#  @BPharmCatalyst BioPharmCatalyst BioPharmCatalyst posts on X about strong, $incy, $qncx, $fold the most. They currently have [------] followers and [---] posts still getting attention that total [-----] engagements in the last [--] hours. ### Engagements: [-----] [#](/creator/twitter::56121651/interactions)  - [--] Week [------] -40% - [--] Month [------] +81% - [--] Months [-------] -73% - [--] Year [---------] -51% ### Mentions: [--] [#](/creator/twitter::56121651/posts_active)  - [--] Week [--] -24% - [--] Month [--] +33% - [--] Months [---] -11% - [--] Year [---] +1.40% ### Followers: [------] [#](/creator/twitter::56121651/followers)  - [--] Week [------] +0.01% - [--] Month [------] +0.25% - [--] Months [------] +2.40% - [--] Year [------] +5% ### CreatorRank: [-------] [#](/creator/twitter::56121651/influencer_rank)  ### Social Influence **Social category influence** [stocks](/list/stocks) 67.36% [cryptocurrencies](/list/cryptocurrencies) 28.47% [finance](/list/finance) 22.22% [countries](/list/countries) 2.78% [technology brands](/list/technology-brands) 1.39% [currencies](/list/currencies) 1.39% [exchanges](/list/exchanges) 0.69% **Social topic influence** [strong](/topic/strong) #2460, [$incy](/topic/$incy) 5.56%, [$qncx](/topic/$qncx) #14, [$fold](/topic/$fold) 4.86%, [$wint](/topic/$wint) 4.86%, [$srpt](/topic/$srpt) 4.86%, [events](/topic/events) 4.86%, [$clsd](/topic/$clsd) 4.17%, [$slrx](/topic/$slrx) 4.17%, [acquisition](/topic/acquisition) 4.17% **Top accounts mentioned or mentioned by** [@mwb741](/creator/undefined) [@yusufhameed](/creator/undefined) [@chasingthealpha](/creator/undefined) [@libraryinvestor](/creator/undefined) [@auditor112017](/creator/undefined) [@markmarkuu](/creator/undefined) [@grok](/creator/undefined) **Top assets mentioned** [Incyte Corporation (INCY)](/topic/$incy) [Amicus Therapeutics, Inc (FOLD)](/topic/$fold) [Sarepta Therapeutics, Inc. (SRPT)](/topic/$srpt) [Eli Lilly and Company (LLY)](/topic/$lly) [BioMarin Pharmaceutical, Inc. (BMRN)](/topic/$bmrn) [Cytokinetics Inc. (CYTK)](/topic/$cytk) [IO Biotech, Inc. (IOBT)](/topic/$iobt) [apM Coin (APM)](/topic/$apm) [Ionis Pharmaceuticals, Inc. Common Stock (IONS)](/topic/$ions) [Exelixis Inc (EXEL)](/topic/$exel) [Contineum Therapeutics, Inc (CTNM)](/topic/$ctnm) [Novavax Inc (NVAX)](/topic/$nvax) [Anebulo Pharmaceuticals, Inc. (ANEB)](/topic/$aneb) [CheckDot (CDT)](/topic/$cdt) [Evotec SE (EVO)](/topic/$evo) [Invivyd, Inc. (IVVD)](/topic/$ivvd) [Agios Pharmaceuticals, Inc. (AGIO)](/topic/$agio) [Biohaven Pharmaceutical Holding Company Ltd. (BHVN)](/topic/$bhvn) [Elevai Labs, Inc. (ELAB)](/topic/$elab) [ADiTx Therapeutics, Inc. (ADTX)](/topic/$adtx) [LYRA (LYRA)](/topic/$lyra) [Abivax SA (ABVX)](/topic/$abvx) [Shuttle Pharmaceuticals Holdings, Inc. (SHPH)](/topic/$shph) [Denali Therapeutics Inc. Common Stock (DNLI)](/topic/$dnli) [Rallybio Corporation (RLYB)](/topic/$rlyb) [Sagimet Biosciences Inc. (SGMT)](/topic/$sgmt) [Merck & Co., Inc. (MRK)](/topic/$mrk) [Adlai Nortye Ltd (ANL)](/topic/$anl) [Corcept Therapeutics Inc. (CORT)](/topic/$cort) [Pharming Group N.V. (PHAR)](/topic/$phar) [Align Technology, Inc. (ALGN)](/topic/$algn) [Novo-Nordisk (NVO)](/topic/$nvo) [Evommune, Inc. (EVMN)](/topic/$evmn) [SuperRare (RARE)](/topic/$rare) [Cognition Therapeutics, Inc. (CGTX)](/topic/$cgtx) [AstraZeneca PLC (AZN)](/topic/$azn) [Synthetify (SNY)](/topic/$sny) [Novartis AG (NVS)](/topic/$nvs) [bioAffinity Technologies, Inc. (BIAF)](/topic/$biaf) [Array Technologies, Inc. (ARRY)](/topic/$arry) [Alkermes Inc. plc (ALKS)](/topic/$alks) [Seagen Inc (SGEN)](/topic/$sgen) [Immunogen Inc (IMGN)](/topic/$imgn) [Upstream Bio, Inc. (UPB)](/topic/$upb) [CalciMedica, Inc. (CALC)](/topic/$calc) [GH Research PLC (GHRS)](/topic/$ghrs) [AltLayer (ALT)](/topic/$alt) ### Top Social Posts Top posts by engagements in the last [--] hours "$UPB reported Phase [--] VALIANT trial results for verekitug in severe asthma showing statistically significant reductions in exacerbation rates (up to 56%) and meaningful improvements in lung function and FeNO across key dosing regimens. $UPB $QNCX $STIM $ELAB $BFRI $MRNA $HURA $PHIO $AIM $DBVT See More Pre-market Movers https://www.biopharmcatalyst.com/news/2026/upstream-bio-upb-phase-2-data-quince-qncx-strategic-alternatives https://www.biopharmcatalyst.com/news/2026/upstream-bio-upb-phase-2-data-quince-qncx-strategic-alternatives" [X Link](https://x.com/BPharmCatalyst/status/2021580039637074077) 2026-02-11T13:40Z 30.7K followers, [----] engagements "$EVAX will present new biomarker and immune data for its personalized cancer vaccine EVX-01 in advanced melanoma at SITC [----] complementing upcoming two-year efficacy results from its Phase [--] KEYTRUDA combination trial being presented at ESMO [----]. $PALI $ANRO $OVID $IMAB $BOLT $EVAX $APLIF $CLNN $SPRC $OCEA See More Biotech Updates👇 https://www.biopharmcatalyst.com/news/2025/alto-neuroscience-anro-fast-track-designation-evaxion-evax-esmo-data https://twitter.com/i/web/status/1974210485022085549" [X Link](https://x.com/BPharmCatalyst/status/1974210485022085549) 2025-10-03T20:30Z 30.7K followers, [----] engagements "$ALUR reported initial 12-month results from a study combining its Smart Capsule program with low-dose tirzepatide showing 23% average total weight loss and a 14% increase in lean body mass with full patient adherence and no early discontinuations $ALUR $CTNM $ESPR $CMND $KTTA $TPST $KZIA $PMBC $CLSD $ADTX See More Biotech Updates👇 https://www.biopharmcatalyst.com/news/2025/quantum-biopharma-qntm-30-lawsuit-allurion-technologies-alur-31-data https://twitter.com/i/web/status/1993432139363197340" [X Link](https://x.com/BPharmCatalyst/status/1993432139363197340) 2025-11-25T21:30Z 30.7K followers, [----] engagements "$HURA entered a definitive agreement to raise https://www.biopharmcatalyst.com/news/2025/wave-life-wve-phase-1-data-structure-therapeutics-gpcr-phase-2-weight-loss-data https://www.biopharmcatalyst.com/news/2025/wave-life-wve-phase-1-data-structure-therapeutics-gpcr-phase-2-weight-loss-data" [X Link](https://x.com/BPharmCatalyst/status/1998505524837380129) 2025-12-09T21:30Z 30.7K followers, [----] engagements "$CYTK announced that the FDA has approved MYQORZO (aficamten) [--] mg [--] mg [--] mg [--] mg tablets for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and symptoms. $FOLD $GALT $MGRX $CYTK $SAVA $GANX $CALC $BYSI $GOVX $PBM See More Biotech Updates👇 https://www.biopharmcatalyst.com/news/2025/amicus-fold-acquired-by-biomarin-galectin-galt-fda-feedback https://www.biopharmcatalyst.com/news/2025/amicus-fold-acquired-by-biomarin-galectin-galt-fda-feedback" [X Link](https://x.com/BPharmCatalyst/status/2002130420565975472) 2025-12-19T21:34Z 30.7K followers, [----] engagements "$GHRS announced that the FDA has lifted the clinical hold on its Investigational New Drug Application (IND) for GH001. Phase [--] is planned for [----]. $GHRS $RDHL $ALT $ZBIO $SLRX $NMRA $CNTX $TENX $PLRZ $GOVX See More Pre-market Movers https://www.biopharmcatalyst.com/news/2026/gh-research-ghrs-hold-lifted-altimmune-alt-breakthrough-therapy-designation https://www.biopharmcatalyst.com/news/2026/gh-research-ghrs-hold-lifted-altimmune-alt-breakthrough-therapy-designation" [X Link](https://x.com/BPharmCatalyst/status/2008171703612928050) 2026-01-05T13:40Z 30.7K followers, [----] engagements "$TIL announced that its subsidiary Axion Bio has discontinued development of AXN-2510 and terminated its license agreement with ImmuneOnco returning all rights to ImmuneOnco while retaining a limited license solely to wind down clinical activities. $TIL $ALMS $CYCN $DRUG $RNAZ $KALA $WVE $ARWR $RDHL $INM See More Pre-market Movers https://www.biopharmcatalyst.com/news/2026/instil-til-terminated-license-agreement-alumis-alms-phase-3-data http://1541.HK http://1541.HK https://www.biopharmcatalyst.com/news/2026/instil-til-terminated-license-agreement-alumis-alms-phase-3-data http://1541.HK" [X Link](https://x.com/BPharmCatalyst/status/2008534078182535419) 2026-01-06T13:40Z 30.7K followers, [----] engagements "$CGON announced that topline Phase [--] data from the PIVOT-006 trial evaluating cretostimogene as adjuvant monotherapy in intermediate-risk NMIBC is now expected in 1H [----] nearly a year ahead of schedule due to rapid enrollment. As the first randomized registrational trial in this underserved patient group the study's accelerated timeline highlights strong clinical interest and significant unmet need potentially positioning cretostimogene as the first FDA-approved option for this indication. $AQST $CGON $QURE $IBIO $KALV $LQDA $ZVSA $ELVN $GRI $WINT See More Biotech Updates👇" [X Link](https://x.com/BPharmCatalyst/status/2009739555931406705) 2026-01-09T21:30Z 30.7K followers, [----] engagements "$LYRA has suspended development of LYR-210 for chronic rhinosinusitis and is implementing a full workforce reduction retaining only key executives as consultants while pursuing strategic alternatives with SSG Capital Advisors. The move effectively ends active operations as the company shifts focus to preserving capital and exploring options for its lead asset. $LYRA $DAWN $ABVX $BDSX $TEM $ADPT $JAGX $IRIX $MESO $WOK See More Pre-market Movers https://www.biopharmcatalyst.com/news/2026/lyra-therapeutics-lyra-suspended-lyr-210-development-day-one-dawn-revenue-update" [X Link](https://x.com/BPharmCatalyst/status/2010708407460704499) 2026-01-12T13:40Z 30.7K followers, [----] engagements "$ATRA received an FDA Complete Response Letter for EBVALLO reversing prior alignment by now deeming the single-arm ALLELE trial insufficient to support accelerated approval for EBV+ PTLD. $ATRA $LYRA $BIOA $DAWN $BDSX $FHTX $CLRB $FBRX $WINT $SHPH See More Biotech Updates👇 https://www.biopharmcatalyst.com/news/2026/atara-atra-57-crl-lyra-lyra-45-lyr-210-suspended https://www.biopharmcatalyst.com/news/2026/atara-atra-57-crl-lyra-lyra-45-lyr-210-suspended" [X Link](https://x.com/BPharmCatalyst/status/2010826740742897682) 2026-01-12T21:30Z 30.7K followers, [----] engagements "$XTLB is acquiring 85% of NeuroNOS from $XAIR gaining a platform for autism biology and two FDA orphan drug designations (PMS and glioblastoma). With leadership including Nobel Laureates and Prof. Haitham Amal XTL enters the high-need autism market which affects [--] in [--] U.S. children and lacks disease-modifying therapies. $DCOY $XTLB $BCTX $TRAW $TVTX $SPRC $IMRN $ERAS $SXTC $RGC See More Biotech Updates👇 https://www.biopharmcatalyst.com/news/2026/xtl-biopharmaceuticals-xtlb-50-xair-deal-decoy-dcoy-41-partnership" [X Link](https://x.com/BPharmCatalyst/status/2011189109541204261) 2026-01-13T21:30Z 30.7K followers, [----] engagements "BioPharmCatalyst Weekly #Watchlist BioPharmCatalyst Weekly Watchlist: Key PDUFA and Regulatory Catalysts for the next [--] months $AXSM $RGNX $REPL $RCKT $RYTM $ARVN $TVTX $MNKD $DNLI $ACHV https://www.biopharmcatalyst.com/news/2026/biopharmcatalyst-weekly-watchlist-key-pdufa-and-regulatory-catalysts-for-the-next-6-months-2 https://www.biopharmcatalyst.com/news/2026/biopharmcatalyst-weekly-watchlist-key-pdufa-and-regulatory-catalysts-for-the-next-6-months-2" [X Link](https://x.com/BPharmCatalyst/status/2012275860695355640) 2026-01-16T21:28Z 30.7K followers, [----] engagements "$LSTA announced it has signed a binding term sheet for a potential acquisition by private biotech firm Kuva Labs for up to $53 million. Kuva will pay $4.00 per share in cash representing an 85% premium to Lisatas prior closing price $LSTA $PBM $ZURA $IOBT $NVAX $VERO $ADTX $CUE $AKAN $LEGN See More Biotech Updates👇 https://www.biopharmcatalyst.com/news/2026/psyence-pbm-reverse-stock-split-postponed-lisata-therapeutics-acquired-by-kuva-labs https://www.biopharmcatalyst.com/news/2026/psyence-pbm-reverse-stock-split-postponed-lisata-therapeutics-acquired-by-kuva-labs" [X Link](https://x.com/BPharmCatalyst/status/2014088241473896524) 2026-01-21T21:30Z 30.7K followers, [----] engagements "BioPharmCatalyst Weekly #Watchlist BioPharmCatalyst Weekly Watchlist: Key mid-2026 and Other Near-term Catalysts $NTLA $RLYB $MNOV $SDGR $OCS $BMEA $SGMT $AVBP $AVIR $CTNM https://www.biopharmcatalyst.com/news/2026/biopharmcatalyst-weekly-watchlist-key-mid-2026-and-other-near-term-catalysts https://www.biopharmcatalyst.com/news/2026/biopharmcatalyst-weekly-watchlist-key-mid-2026-and-other-near-term-catalysts" [X Link](https://x.com/BPharmCatalyst/status/2014810459178717461) 2026-01-23T21:20Z 30.7K followers, [----] engagements "$MRK has ended acquisition talks with $RVMD after failing to agree on a valuation with discussions reportedly valuing the biotech at around $30 billion. $SXTP $RVMD $REVB $SRPT $IOBT $COGT $ABOS $INMD $TBPH $MESO See More Pre-market Movers https://www.biopharmcatalyst.com/news/2026/revolution-medicines-rvmd-acquistion-talks-with-mrk-end-60-degrees-pharmaceuticals-sxtp-delisting https://www.biopharmcatalyst.com/news/2026/revolution-medicines-rvmd-acquistion-talks-with-mrk-end-60-degrees-pharmaceuticals-sxtp-delisting" [X Link](https://x.com/BPharmCatalyst/status/2015781842121576463) 2026-01-26T13:40Z 30.7K followers, [----] engagements "$CALC discontinued its Phase [--] KOURAGE trial of Auxora in AKI with AHRF after an IDMC-recommended safety review flagged concerns warranting study design reevaluation despite no drug-related deaths or serious adverse events. The company will analyze unblinded data to guide potential future development in AKI while continuing plans for a pivotal trial in acute pancreatitis and advancing its second CRAC channel inhibitor. $CALC $ALT $RADX $PHGE $JUNS $STEX $FEED $KRRO $HIND $NUWE See More Pre-market Movers" [X Link](https://x.com/BPharmCatalyst/status/2016506616212779495) 2026-01-28T13:40Z 30.7K followers, [----] engagements "BioPharmCatalyst Weekly Watchlist: Key mid-2026 and Other Near-Term Catalysts $NTLA $RLYB $MNOV $SDGR $OCS $BMEA $SGMT $AVBP $AVIR $CTNM https://www.biopharmcatalyst.com/news/2026/biopharmcatalyst-weekly-watchlist-key-mid-2026-and-other-near-term-catalysts https://www.biopharmcatalyst.com/news/2026/biopharmcatalyst-weekly-watchlist-key-mid-2026-and-other-near-term-catalysts" [X Link](https://x.com/BPharmCatalyst/status/2016911678902776129) 2026-01-29T16:29Z 30.7K followers, [----] engagements "$ANL was initiated with a Buy rating and $11 price target by Lucid Capital citing its pan-RAS inhibitor AN9025 as a key potential value driver as the asset becomes de-risked $VIVS $ANL $CORT $APRE $PMN $LXRX $ANEB $APM $QNCX $DRMA See More Biotech Updates👇 https://www.biopharmcatalyst.com/news/2026/vivosim-labs-vivs-commercial-access-china-sxt-pharmaceuticals-sxtc-reverse-split https://www.biopharmcatalyst.com/news/2026/vivosim-labs-vivs-commercial-access-china-sxt-pharmaceuticals-sxtc-reverse-split" [X Link](https://x.com/BPharmCatalyst/status/2017358617410953713) 2026-01-30T22:05Z 30.7K followers, [----] engagements "BioPharmCatalyst Weekly #Watchlist BioPharmCatalyst Weekly Watchlist: Key Catalysts Over The Next Two months $GOSS $RGNX $PVLA $KOD $ALDX $ACET $TBPH $FGEN $KPTI $ALZN https://www.biopharmcatalyst.com/news/2026/biopharmcatalyst-weekly-watchlist-key-catalysts-over-the-next-two-months https://www.biopharmcatalyst.com/news/2026/biopharmcatalyst-weekly-watchlist-key-catalysts-over-the-next-two-months" [X Link](https://x.com/BPharmCatalyst/status/2017628942518431778) 2026-01-31T16:00Z 30.7K followers, [----] engagements "$ELAB completed its third CNC shop acquisition buying SVM Machining for $2.25M plus earnouts expanding its precision manufacturing platform across aerospace medical and semiconductor sectors. $ELAB $EVO $ANL $CRBU $PHAR $APM $CDT $ATOS $HURA $VIVS See More Pre-market Movers https://www.biopharmcatalyst.com/news/2026/pmgc-holdings-elab-acquisition-evotec-evo-analyst-rating https://www.biopharmcatalyst.com/news/2026/pmgc-holdings-elab-acquisition-evotec-evo-analyst-rating" [X Link](https://x.com/BPharmCatalyst/status/2018680952331845963) 2026-02-03T13:40Z 30.7K followers, [----] engagements "$SGMO priced a $25M+ offering amid strong Phase 1/2 STAAR data showing ST-920 improved kidney and cardiac function in Fabry disease supporting a rolling BLA submission to FDA. $SGMO $ELAB $RLYB $ERNA $EVO $RLAY $CDT $EPRX $SXTC $QNCX See More Biotech Updates👇 https://www.biopharmcatalyst.com/news/2026/sangamo-therapeutics-sgmo-31-private-placement-pmgc-holdings-elab-40-acquisition https://www.biopharmcatalyst.com/news/2026/sangamo-therapeutics-sgmo-31-private-placement-pmgc-holdings-elab-40-acquisition" [X Link](https://x.com/BPharmCatalyst/status/2018801747314061740) 2026-02-03T21:40Z 30.7K followers, [----] engagements "$NVST reported strong Q4 [----] results with core sales growth of 10.8% and a 22% increase in adjusted EBITDA to $111 million. Adjusted EPS rose 58% year-over-year to $0.38. For full-year [----] core sales grew 6.5% and adjusted EBITDA increased 26% reaching $372 million. CEO Paul Keel highlighted solid growth across all major businesses and geographies improved employee engagement and $166 million returned to shareholders via stock buybacks. Envista guided for [----] adjusted EPS of $1.35$1.45 core sales growth of 24% and free cash conversion of" [X Link](https://x.com/BPharmCatalyst/status/2019768096039285197) 2026-02-06T13:40Z 30.7K followers, [----] engagements "$VTYX surged after hours on reports that $LLY is in advanced talks to acquire the company with a deal potentially imminent. Ventyx focused on oral therapies for inflammatory diseases currently has a $600M market cap. $VTYX $ALMS $CYCN $TIL $ACRV $DRUG $RGC $BIOA $MREO $BNR See More Biotech Updates👇 https://www.biopharmcatalyst.com/news/2026/alumis-alms-phase-3-data-cyclerion-cycn-collaboration https://www.biopharmcatalyst.com/news/2026/alumis-alms-phase-3-data-cyclerion-cycn-collaboration" [X Link](https://x.com/BPharmCatalyst/status/2008652398961569956) 2026-01-06T21:30Z 30.7K followers, [----] engagements "$IMRX announced encouraging updated Phase 2a data for Atebimetinib in combination with modified gemcitabine/nab-paclitaxel in first-line metastatic pancreatic cancer showing a 64% 12-month overall survival rate vs. https://www.biopharmcatalyst.com/news/2026/immuneering-imrx-phase-2a-data-eli-lilly-lly-will-acquire-ventyx-biosciences-vtyx https://www.biopharmcatalyst.com/news/2026/immuneering-imrx-phase-2a-data-eli-lilly-lly-will-acquire-ventyx-biosciences-vtyx" [X Link](https://x.com/BPharmCatalyst/status/2009258857718034567) 2026-01-08T13:40Z 30.7K followers, [----] engagements "$AQST announced receipt of a CRL from the FDA for its sublingual film epinephrine treatment Anaphylm citing human factors deficiencies related to packaging and administration including difficulty opening the pouch and incorrect film placement. $AQST $THAR $SER $PHAR $MOLN $HIND $SXTC $VERO $APRE $NUWE See More Pre-market Movers https://www.biopharmcatalyst.com/news/2026/aquestive-therapeutics-aqst-crl-pharming-group-phar-crl https://www.biopharmcatalyst.com/news/2026/aquestive-therapeutics-aqst-crl-pharming-group-phar-crl" [X Link](https://x.com/BPharmCatalyst/status/2018318570149585241) 2026-02-02T13:40Z 30.7K followers, [----] engagements "$ALGN topped Wall Street estimates for both earnings and revenue. Driven by strong demand for its Invisalign system Align reported Q4 adjusted earnings of $3.29 per share on revenue of $1.05 billionabove analyst expectations of $2.97 per share and $1.03 billion. Clear Aligner revenue grew 5.5% to $838 million. For Q1 Align guided revenue between $1.01 billion and $1.03 billion and projected a 19.5% operating margin slightly below consensus. While Needhams David Saxon maintained a Hold rating he noted the outlook was fairly achievable amid strong U.S. and international sales. $ALGN $ALXO $TPST" [X Link](https://x.com/BPharmCatalyst/status/2019405726620250592) 2026-02-05T13:40Z 30.7K followers, [----] engagements "$ALGN topped Wall Street estimates for both earnings and revenue. Driven by strong demand for its Invisalign system Align reported Q4 adjusted earnings of $3.29 per share on revenue of $1.05 billionabove analyst expectations of $2.97 per share and $1.03 billion. Clear Aligner revenue grew 5.5% to $838 million. For Q1 Align guided revenue between $1.01 billion and $1.03 billion and projected a 19.5% operating margin slightly below consensus. While Needhams David Saxon maintained a Hold rating he noted the outlook was fairly achievable amid strong U.S. and international sales. $ALGN $ALXO $TPST" [X Link](https://x.com/BPharmCatalyst/status/2019427505355059236) 2026-02-05T15:06Z 30.7K followers, [----] engagements "$RGNX announced the FDA has issued a Complete Response Letter (CRL) for its BLA submission of RGX-121 for MPS II (Hunter syndrome) citing concerns over patient eligibility criteria use of external controls and surrogate endpoints. $RGNX $TNON $HUMA $LNAI $BCAB $QNCX $ENSC $HURA $ERNA $LYRA See More Biotech Updates👇 https://www.biopharmcatalyst.com/news/2026/regenxbio-rgnx-halt-complete-response-letter-crl-humacyte-huma-30-dod-funding https://www.biopharmcatalyst.com/news/2026/regenxbio-rgnx-halt-complete-response-letter-crl-humacyte-huma-30-dod-funding" [X Link](https://x.com/BPharmCatalyst/status/2020975760190628069) 2026-02-09T21:39Z 30.7K followers, [----] engagements "$PHAR announced that the FDA issued a Complete Response Letter for the sNDA to expand Joenja (leniolisib) for APDS patients aged [---] citing concerns about potential underexposure in lower-weight children and an analytical testing method. $AQST $CATX $PHAR $SER $HIND $SGMT $SXTC $APLM $BCAB $ATOS See More Biotech Updates👇 https://www.biopharmcatalyst.com/news/2026/aquestive-therapeutics-crl-perspective-therapeutics-catx-offering https://www.biopharmcatalyst.com/news/2026/aquestive-therapeutics-crl-perspective-therapeutics-catx-offering" [X Link](https://x.com/BPharmCatalyst/status/2018437925508096112) 2026-02-02T21:34Z 30.7K followers, [----] engagements "$IRON received a CRL from the FDA for bitopertin in erythropoietic protoporphyria (EPP) with the agency acknowledging that the Phase [--] AURORA and BEACON trials showed significant reductions in whole blood metal-free PPIX and strong mechanistic support for the biomarker but concluding the data did not demonstrate a clear association between PPIX reductions and sunlight exposure-based clinical endpoints. The FDA indicated that results from the ongoing Phase [--] APOLLO trial could support traditional approval with topline data expected in Q4 [----]. The company plans to request a Type A meeting with" [X Link](https://x.com/BPharmCatalyst/status/2022406484710060253) 2026-02-13T20:24Z 30.7K followers, [----] engagements "$PHRRF announced that the FDA has approved the Company's ketamine product herein referred to as KETARx on August 8th [----] for its indicated uses in surgical pain management. https://www.biopharmcatalyst.com/company/PHRRF/news/287382 https://www.biopharmcatalyst.com/company/PHRRF/news/287382" [X Link](https://x.com/BPharmCatalyst/status/1954898307420934649) 2025-08-11T13:30Z 30.7K followers, [----] engagements "$CLSD filed for Chapter [--] bankruptcy and will pursue a sale of its assets under Section [---] aiming to maximize stakeholder value via its SCS Microinjector platform five licensing deals with royalty potential and clinical-stage programs including Phase 3-ready CLS-AX for wet AMD and IND-ready assets in geographic atrophy and DME. $CLSD $ENLV $PMN $INSP $NVO $GNTA $ADTX $NAOV $SHPH $OABI See More Pre-market Movers https://www.biopharmcatalyst.com/news/2025/clearside-biomedical-clsd-chapter-11-enlivex-therapeutics-enlv-phase-2a-data-pipe" [X Link](https://x.com/BPharmCatalyst/status/1992951396044316939) 2025-11-24T13:40Z 30.7K followers, [----] engagements "$MOVE reported that its merger partner Corvex secured a long-term lease for Nvidia H200 GPUs. The companies announced an all-stock merger in November with Corvex shareholders to own https://www.biopharmcatalyst.com/news/2026/greenwich-lifesciences-glsi-manufacturing-update-gri-bio-gri-reverse-stock-split https://www.biopharmcatalyst.com/news/2026/greenwich-lifesciences-glsi-manufacturing-update-gri-bio-gri-reverse-stock-split" [X Link](https://x.com/BPharmCatalyst/status/2014694674972229985) 2026-01-23T13:40Z 30.7K followers, [----] engagements "$ADAG ended [----] with $74.5M in cash funding operations into late [----]. A Q1 [----] data update is expected from the Phase 1b/2 study of muzastotug + pembrolizumab in 3L+ MSS colorectal cancer. In [----] muzastotug received FDA Fast Track designation and showed promising early efficacy/safety. $MOVE $ADAG $REVB $PRFX $CHRS $BHC $ANL $SCNI $IOBT $BNR See More Biotech Updates👇 https://www.biopharmcatalyst.com/news/2026/adagene-adag-23-update-movano-move-140-nvidia-deal https://www.biopharmcatalyst.com/news/2026/adagene-adag-23-update-movano-move-140-nvidia-deal" [X Link](https://x.com/BPharmCatalyst/status/2014813944527876547) 2026-01-23T21:34Z 30.7K followers, [----] engagements "$ALGN topped Wall Street estimates for both earnings and revenue. Driven by strong demand for its Invisalign system Align reported Q4 adjusted earnings of $3.29 per share on revenue of $1.05 billionabove analyst expectations of $2.97 per share and $1.03 billion. Clear Aligner revenue grew 5.5% to $838 million. For Q1 Align guided revenue between $1.01 billion and $1.03 billion and projected a 19.5% operating margin slightly below consensus. While Needhams David Saxon maintained a Hold rating he noted the outlook was fairly achievable amid strong U.S. and international sales. $ALGN $ALXO $TPST" [X Link](https://x.com/anyuser/status/2019426910808268997) 2026-02-05T15:04Z 30.7K followers, [----] engagements "BioPharmCatalyst Weekly #Watchlist BioPharmCatalyst Weekly Watchlist: Anticipated Key Catalysts Due Over Next [--] Months $AXSM $DNLI $MIRM $NBTX $RYTM $ADCT $VRDN $OCS $AVIRI $CTMN https://www.biopharmcatalyst.com/news/2026/biopharmcatalyst-weekly-watchlist-anticipated-key-catalysts-due-over-next-6-months-2 https://www.biopharmcatalyst.com/news/2026/biopharmcatalyst-weekly-watchlist-anticipated-key-catalysts-due-over-next-6-months-2" [X Link](https://x.com/BPharmCatalyst/status/2019890098771501524) 2026-02-06T21:45Z 30.7K followers, [----] engagements "$ERNA priced a $10.5M best-efforts public offering of 21M shares (or equivalents) and accompanying warrants at $0.50 per unit with warrants exercisable at $0.68 and expiring either five years post-issuance or [---] days after initial ERNA-101 Phase [--] cohort data release. Proceeds will fund development programs and operations with potential for $14.3M in additional gross proceeds if warrants are fully exercised. $ERNA $PLSE $ANEB $NVST $ATPC $ROIV $HURA $DNA $ESLA $ENVB See More Biotech Updates👇" [X Link](https://x.com/BPharmCatalyst/status/2019890474249503200) 2026-02-06T21:46Z 30.7K followers, [----] engagements "$TNON reaffirmed its strong [----] revenue outlook projecting Q4 revenue of $1.45M$1.48M (up https://www.biopharmcatalyst.com/news/2026/tenon-medical-tnon-earnings-guidance-artelo-biosciences-artl-equity-purchase-agreement https://www.biopharmcatalyst.com/news/2026/tenon-medical-tnon-earnings-guidance-artelo-biosciences-artl-equity-purchase-agreement" [X Link](https://x.com/BPharmCatalyst/status/2020855258885292385) 2026-02-09T13:40Z 30.7K followers, [----] engagements "$EVMN reported Phase 2a results for EVO301 in moderate-to-severe atopic dermatitis meeting the primary efficacy endpoint with a 33% placebo-adjusted EASI improvement at week [--] and 23% of patients achieving IGA 0/1. The IL-18 inhibitor showed rapid statistically significant efficacy at weeks [--] [--] and [--] with a clean safety profile supporting advancement to a Phase 2b dose-ranging trial and broader development plans. $ABP $QNCX $PSNL $NKTR $PHIO $MIRA $PHG $HURA $TECX $ENSC See More Pre-market Movers" [X Link](https://x.com/BPharmCatalyst/status/2021217660395041235) 2026-02-10T13:40Z 30.7K followers, [----] engagements "$QNCX announced that it is hiring LifeSci Capital to explore strategic alternatives including partnerships M&A licensing or balance-sheet restructuring though no outcome or timeline has been disclosed. $QNCX $EVMN $NKTR $PHIO $BRTX $PHGE $HURA $LNAI $ENSC $TECX See More Biotech Updates👇 https://www.biopharmcatalyst.com/news/2026/quince-qncx-306-strategic-alternatives-nektar-nktr-51-phase-2b-data https://www.biopharmcatalyst.com/news/2026/quince-qncx-306-strategic-alternatives-nektar-nktr-51-phase-2b-data" [X Link](https://x.com/BPharmCatalyst/status/2021336238649901433) 2026-02-10T21:31Z 30.7K followers, [----] engagements "$NVCR shares are up following FDA approval of Optune Pax for locally advanced pancreatic cancer marking the first new treatment in decades. The wearable device used with gemcitabine and nab-paclitaxel improved overall survival in a Phase [--] trial. $NVCR $QNCX $VKTX $MCRB $BRTX $BBIO $CTNM $PLRZ $ICLR $ABP See More Pre-market Movers https://www.biopharmcatalyst.com/news/2026/novocure-nvcr-approval-bridgebio-bbio-phase-3-dat https://www.biopharmcatalyst.com/news/2026/novocure-nvcr-approval-bridgebio-bbio-phase-3-dat" [X Link](https://x.com/BPharmCatalyst/status/2021942425384579423) 2026-02-12T13:40Z 30.7K followers, [----] engagements "$IMUX issued warrants to purchase up to [---------] shares (or pre-funded warrants) at $0.873/share potentially raising an additional $200 million. The warrants expire [--] days post-Phase [--] ENSURE top-line data announcement or February [--] [----]. This private placement expected to close around February [--] [----] supports Immunic's transition to the commercial stage. $IMUX $VTGN $CHRS $QNCX $BIO $OKYO $JSPR $BRTX $ABP $ARTL See More Pre-market Movers https://www.biopharmcatalyst.com/news/2026/immunic-imux-warrants-coherus-oncology-chrs-offering" [X Link](https://x.com/BPharmCatalyst/status/2022304828211216840) 2026-02-13T13:40Z 30.7K followers, [----] engagements "BioPharmCatalyst Weekly #Watchlist BioPharmCatalyst Weekly Watchlist: Key Phase [--] catalysts left for the quarter $OCUL $BCRX $GOSS $BCDA $KOD $TBPH $KPTI $PVLA https://www.biopharmcatalyst.com/news/2026/biopharmcatalyst-weekly-watchlist-key-phase-3-catalysts-left-for-the-quarter https://www.biopharmcatalyst.com/news/2026/biopharmcatalyst-weekly-watchlist-key-phase-3-catalysts-left-for-the-quarter" [X Link](https://x.com/BPharmCatalyst/status/2022423796184158417) 2026-02-13T21:33Z 30.7K followers, [----] engagements "$ONCY reported significant coordinated insider buying across all executive and board levels on February [----] [----]. Purchases between $0.83 and $0.86 per share signal strong confidence at the current price; shares closed up 26%. $IRON $ONCY $PHIO $CHRS $OKYO $EVMN $AIM $ICLR $INTS $UPB See More Biotech Updates👇 https://www.biopharmcatalyst.com/news/2026/disc-iron-22-complete-response-letter-crl-oncolytics-oncy-27-insider-buys https://www.biopharmcatalyst.com/news/2026/disc-iron-22-complete-response-letter-crl-oncolytics-oncy-27-insider-buys" [X Link](https://x.com/BPharmCatalyst/status/2022424467050320005) 2026-02-13T21:35Z 30.7K followers, [---] engagements "Want more info analysis and biotech news straight to your inbox Sign up for our FREE Daily and Weekly newsletters here: https://bit.ly/BPCNewsletters https://bit.ly/BPCNewsletters" [X Link](https://x.com/BPharmCatalyst/status/1944834947291726230) 2025-07-14T19:02Z 29.7K followers, [----] engagements "$SRPT announced a strategic restructuring to prioritize high-impact programs ensure financial sustainability through [----] and focus on siRNA platform opportunities. The plan includes $400M in annual cost savings and a 36% workforce reduction (500 employees) aiming for long-term growth and profitability. See More Biotech Updates👇 $APM $CUE $CYCC $NUWE $QLGN $RPTX $GANX $CGTX $IKNA https://www.biopharmcatalyst.com/news/2025/aptorum-group-apm-100-all-stock-merger-nuwellis-nuwe-131-patent https://www.biopharmcatalyst.com/news/2025/aptorum-group-apm-100-all-stock-merger-nuwellis-nuwe-131-patent" [X Link](https://x.com/BPharmCatalyst/status/1945581687116648692) 2025-07-16T20:29Z 29.9K followers, [----] engagements "Want more info analysis and biotech news straight to your inbox Sign up for our FREE Daily and Weekly newsletters here: https://bit.ly/BPCNewsletters https://bit.ly/BPCNewsletters" [X Link](https://x.com/BPharmCatalyst/status/1945600565678879123) 2025-07-16T21:44Z 29.9K followers, [----] engagements "$WINT signed a $60M securities purchase agreement led by Build and Build Corp with the potential to raise a total of $200M to launch a BNB crypto treasury strategy. Subject to shareholder approval Windtree aims to become the first NASDAQ-listed company offering direct BNB token exposure. See More Pre-market Movers 👇 $WINT $SRPT $PRTC $RCKT $NUWE https://www.biopharmcatalyst.com/news/2025/windtree-wint-securities-purchase-agreement-sarepta-srpt-restructuring https://www.biopharmcatalyst.com/news/2025/windtree-wint-securities-purchase-agreement-sarepta-srpt-restructuring" [X Link](https://x.com/BPharmCatalyst/status/1945821738761150765) 2025-07-17T12:23Z 29.9K followers, [----] engagements "$CLSD initiated a strategic review to explore options including asset sales partnerships or M&A to advance its SCS platform; Piper Sandler retained to lead the process. See More Biotech Updates👇 $WINT $SRPT $RCKT $FOLD $MBRX $CLSD $ICU https://www.biopharmcatalyst.com/news/2025/windtree-wint-17-securities-purchase-agreement-clearside-clsd-28-strategic-review https://www.biopharmcatalyst.com/news/2025/windtree-wint-17-securities-purchase-agreement-clearside-clsd-28-strategic-review" [X Link](https://x.com/BPharmCatalyst/status/1945943063223734497) 2025-07-17T20:25Z 30.1K followers, [----] engagements "$TELO reported promising data for Telomir-1 which showed it could reverse epigenetic gene silencing and restore tumor suppressors in human prostate cancer cells outperforming chemotherapy and rapamycin. See More Pre-market Movers 👇 $MESO $CNSP $SRPT $WINT $IINN https://www.biopharmcatalyst.com/news/2025/telomir-telo-telomir-1-data-mesoblast-meso-revenue https://www.biopharmcatalyst.com/news/2025/telomir-telo-telomir-1-data-mesoblast-meso-revenue https://www.biopharmcatalyst.com/news/2025/telomir-telo-telomir-1-data-mesoblast-meso-revenue" [X Link](https://x.com/BPharmCatalyst/status/1946183417592152183) 2025-07-18T12:20Z 30.2K followers, [----] engagements "BioPharmCatalyst Weekly #Watchlist Key Catalysts Due in Mid-2025 $REPL $OTLK $RARE $WINT $ATAI $CYBN $IXHL $TNXP $VYNE $ATHE $PFE $CRDF $PRAX https://www.biopharmcatalyst.com/news/2025/key-catalysts-due-in-mid-2025 https://www.biopharmcatalyst.com/news/2025/key-catalysts-due-in-mid-2025" [X Link](https://x.com/BPharmCatalyst/status/1946585823467717081) 2025-07-19T15:00Z 30.1K followers, [----] engagements "$ITOS to be acquired by Concentra Biosciences for $10.047/share in cash plus a CVR tied to net cash above $475M and potential asset sales; tender offer to begin by Aug [--] [----]. See More Pre-market Movers 👇 $PMN $HSDT $ZIMV $SABS $NCNA $AUTL $EVO https://www.biopharmcatalyst.com/news/2025/promis-pmn-fast-track-designation-helius-hsdt-data https://www.biopharmcatalyst.com/news/2025/promis-pmn-fast-track-designation-helius-hsdt-data" [X Link](https://x.com/BPharmCatalyst/status/1947270385721802761) 2025-07-21T12:20Z 30.1K followers, [----] engagements "$PMN shares closed up after the company announced that PMN310 its lead therapeutic candidate for Alzheimer's received FDA Fast Track designation. See More Biotech Updates👇 $PMN $ZIMV $EVO $SABS $HOOK $SLRX $CLSD $GDTC https://www.biopharmcatalyst.com/news/2025/zimvie-zimv-122-acquired-by-archimed-promis-pmn-154-fast-track-designation https://www.biopharmcatalyst.com/news/2025/zimvie-zimv-122-acquired-by-archimed-promis-pmn-154-fast-track-designation" [X Link](https://x.com/BPharmCatalyst/status/1947400894212886643) 2025-07-21T20:58Z 30K followers, [----] engagements "$REPL received a Complete Response Letter from the FDA for its BLA for RP1 with nivolumab in advanced melanoma citing the IGNYTE trial as inadequate due to patient heterogeneity and confirmatory trial design issues; no safety concerns were noted. Replimune plans to request a Type A meeting to discuss accelerated approval. See More Pre-market Movers 👇 $PMN $QNTM $STRO $GNLX $SPRC https://www.biopharmcatalyst.com/news/2025/replimune-repl-crl-promis-pmn-offering https://www.biopharmcatalyst.com/news/2025/replimune-repl-crl-promis-pmn-offering" [X Link](https://x.com/BPharmCatalyst/status/1947633729318322445) 2025-07-22T12:24Z 29.9K followers, [----] engagements "$ABVX shares are halted following results that its 50mg obefazimod achieved 16.4% pooled placebo-adjusted clinical remission at [--] weeks in Phase [--] ABTECT induction trials for moderate-to-severe UC meeting all key secondary endpoints with favorable safety. Maintenance data is due 2Q [----] ahead of planned NDA/MAA submissions in 2H [----]. The company also delayed 1H [----] financial results from August [--] to September [--] [----]. Preliminary cash and cash equivalents as of June [--] [----] were approximately $71.4 million (unaudited). See More Biotech Updates👇 $IOVA $REPL $PMN $QNTM $STRO $AMIX $ABVX" [X Link](https://x.com/BPharmCatalyst/status/1947761507086864534) 2025-07-22T20:51Z 29.9K followers, [----] engagements "$ANEB announced a proposed reverse stock split at a ratio between 1-for-2500 and 1-for-7500 as part of a plan to go private by reducing its number of shareholders. Stockholders with fewer than the minimum required shares post-split will be cashed out at $3.50 per pre-split share a 91% premium over the July [--] [----] closing price. The split is subject to stockholder approval and other conditions. See More Pre-market Movers 👇 $CLSD $IMNN $PHVS $IOVA $LTRN https://www.biopharmcatalyst.com/news/2025/anebulo-aneb-reverse-stock-split-clearside-biomedical-clsd-canada-approval" [X Link](https://x.com/BPharmCatalyst/status/1947995771069968489) 2025-07-23T12:22Z 29.9K followers, [----] engagements "$CLSD announced that Health Canada has granted approval for XIPERE for suprachoroidal use in the treatment of uveitic macular edema (UME). See More Biotech Updates👇 $ABVX $ANEB $CLSD $IMNN $GHRS $PHVS $IOVA $LTRN https://www.biopharmcatalyst.com/news/2025/abivax-abvx-586-phase-3-data-anebulo-aneb-82-reverse-splite https://www.biopharmcatalyst.com/news/2025/abivax-abvx-586-phase-3-data-anebulo-aneb-82-reverse-splite" [X Link](https://x.com/BPharmCatalyst/status/1948121329154015656) 2025-07-23T20:41Z 30.1K followers, [----] engagements "$ADAP will sell TECELRA lete-cel afami-cel and uza-cel to US WorldMeds for $55M upfront and up to $30M in milestones. US WorldMeds will handle commercialization and development while Adaptimmune focuses on preclinical programs (PRAME CD70 allogeneic) and will restructure. See More Biotech Updates👇 $CELC $ENTX $ADAP $ATHE $STXS $LYEL https://www.biopharmcatalyst.com/news/2025/celcuity-celc-167-phase-3-data-adaptimmune-adap-71-tecelra-sale https://www.biopharmcatalyst.com/news/2025/celcuity-celc-167-phase-3-data-adaptimmune-adap-71-tecelra-sale" [X Link](https://x.com/BPharmCatalyst/status/1949933792086401053) 2025-07-28T20:43Z 30K followers, [----] engagements "$CLDI received FDA Fast Track designation for CLD-201 (SuperNova) its allogeneic adipose stem-cell loaded oncolytic virus for the treatment of soft tissue sarcoma. See More Pre-market Movers 👇 $DRRX $SCNI $SLRX $FULC $SRPT $APLS $NVO $ADAP $NEO https://www.biopharmcatalyst.com/news/2025/durect-drrx-acquired-by-bausch-bhc-calidi-cldi-fast-track-designation-ftd https://www.biopharmcatalyst.com/news/2025/durect-drrx-acquired-by-bausch-bhc-calidi-cldi-fast-track-designation-ftd" [X Link](https://x.com/BPharmCatalyst/status/1950169710688944166) 2025-07-29T12:21Z 30K followers, [----] engagements "$SNGX reported results from an eight-patient Phase 2a study of SGX945 (dusquetide) in Behets-related ulcers showing a 40% efficacy improvement over historical placebo with no drug-related adverse events. Benefits were comparable to apremilast and persisted post-treatment. The company plans to reformulate for subcutaneous dosing and pursue a placebo-controlled Phase [--] trial. See More Pre-market Movers 👇 $ENSC $IHXL $DYAI $APLS $PBM $PRME https://www.biopharmcatalyst.com/news/2025/soligenix-sngx-phase-2a-data-ensysce-ensc-breakthrough-therapy-designation" [X Link](https://x.com/BPharmCatalyst/status/1950895227264221221) 2025-07-31T12:24Z 30K followers, [----] engagements "$GRI reported 6-week interim biomarker data from its Phase 2a IPF trial of GRI-0621 showing reduced fibrogenesis markers and a net fibrolytic profile in treated patients. The data suggest enhanced ECM remodeling and potential tissue repair. The IDMC recommended the study continue as planned citing no safety concerns and the need for additional data to confirm efficacy versus standard of care. See More Biotech Updates👇 $SNGX $INDV $ALNY $IXHL $GRI $VCEL $APLS $PSTV https://www.biopharmcatalyst.com/news/2025/soligenix-sngx-phase-2a-data-gri-bio-gri-biomarker-dat" [X Link](https://x.com/BPharmCatalyst/status/1951016996381806659) 2025-07-31T20:27Z 30.2K followers, [----] engagements "$BTAI shares closed up after an H.C. Wainwright analyst reiterated a Buy rating and $8 PT citing the imminent top-line readout from the pivotal SERENITY At-Home Phase [--] safety trial of sub-lingual film BXCL501 (IGALMI) in bipolar and schizophrenia agitation. See More Biotech Updates👇 $CASI $BTAI $REPL $PBM $XOMA $SAVA $SINT $XCUR $MURA $VRTX $INMB https://www.biopharmcatalyst.com/news/2025/casi-pharmaceuticals-casi-investigational-new-drug-ind-bioxcel-btai-analyst https://www.biopharmcatalyst.com/news/2025/casi-pharmaceuticals-casi-investigational-new-drug-ind-bioxcel-btai-analyst" [X Link](https://x.com/BPharmCatalyst/status/1952468534723834250) 2025-08-04T20:35Z 30K followers, [----] engagements "$GUTS announced a public offering of common stock and warrants following positive 2-year data for its Revita system in obese T2D patients showing 9.6% median weight loss and 1.6% HbA1c reduction with no serious device-related events; results align with prior studies with interim REMAIN-1 data expected in Q3 [----] and primary endpoints in 2H [----] and underwriters granted a 30-day option to purchase an additional 15%. $PHGE $COSM $LNTH $EOLS $GUTS $GERN $CRDL $MNKD $AIMD See More Biotech Updates👇" [X Link](https://x.com/BPharmCatalyst/status/1953193146419937650) 2025-08-06T20:35Z 30.3K followers, [----] engagements "$EBS exceeded Q2 [----] revenue guidance by $21M and raised the low end/midpoint of full-year profitability outlook citing strong execution of its turnaround plan improved margins and sustained positive cash flow; the company secured seven new biodefense contract modifications and sees continued demand for its naloxone products and medical countermeasures heading into H2. $SANA $LLY $IRWD $XERS $FGEN $EBS $CCCC $AKBA See More Biotech Updates👇 https://www.biopharmcatalyst.com/news/2025/emergent-ebs-earnings-sana-biotechnology-sana-offering" [X Link](https://x.com/BPharmCatalyst/status/1953554324258246686) 2025-08-07T20:30Z 30.2K followers, [----] engagements "$ENTO announced definitive agreements with institutional investors for the purchase and sale of approximately $3 million in pre-funded and common warrants. The transaction was priced at the market under Nasdaq rules. $IOBT $BJDX $NYXH $AVTR See More Pre-market Movers 👇 https://www.biopharmcatalyst.com/news/2025/entero-therapeutics-ento-warrants-io-biotech-iobt-phase-3-data https://www.biopharmcatalyst.com/news/2025/entero-therapeutics-ento-warrants-io-biotech-iobt-phase-3-data" [X Link](https://x.com/BPharmCatalyst/status/1954885570078896550) 2025-08-11T12:40Z 30.1K followers, [----] engagements "$ATNF shares rose after a $156 million private offering boosting its Ethereum reserves. This follows a $425 million placement led by over [--] institutional and crypto investors. The firm will rebrand as ETHZilla Corporation reflecting its focus on ETH. $ATNF $CGTX $XFOR $TNXP $ARCT $VERU $DRIO $MYO See More Biotech https://www.biopharmcatalyst.com/news/2025/180-life-sciences-atnf-private-offering-drio-drio-earnings https://www.biopharmcatalyst.com/news/2025/180-life-sciences-atnf-private-offering-drio-drio-earnings" [X Link](https://x.com/BPharmCatalyst/status/1955368348772086029) 2025-08-12T20:38Z 30K followers, [----] engagements "$CGTX secured FDA alignment on Phase [--] design for zervimesine in mild-to-moderate Alzheimers including p-tau217based patient enrichment six-month treatment duration confirmed endpoints and an open-label extension with two such studies potentially supporting an NDA after Phase [--] data showed 95% slowing of cognitive decline in the enriched population. $ATNF $GBIO $SPRO $SEPN $DERM $CMPX See More Pre-market Movers 👇 https://www.biopharmcatalyst.com/news/2025/180-life-sciences-atnf-crypto-reserves-cognition-therapeutics-cgtx-fda-phase-3-alignment" [X Link](https://x.com/BPharmCatalyst/status/1955610367708520526) 2025-08-13T12:40Z 30.1K followers, [----] engagements "$SNOA launched its HOCl-based diaper rash hydrogel into major U.S. retail channels now available in [----] Walmart stores on Amazon and in large grocery chains marking its first large-scale U.S. OTC consumer product rollout. $SCLX $LIXT $XFOR $CGTX $GBIO $DERM $SPRO See More Biotech Updates👇 https://www.biopharmcatalyst.com/news/2025/sonoma-pharmaceuticals-snoa-46-product-roll-out-scilex-sclx-19-s-4-filing https://www.biopharmcatalyst.com/news/2025/sonoma-pharmaceuticals-snoa-46-product-roll-out-scilex-sclx-19-s-4-filing" [X Link](https://x.com/BPharmCatalyst/status/1955728670422630705) 2025-08-13T20:30Z 30.1K followers, [----] engagements "$PGEN announced that the FDA has approved PAPZIMEOS (zopapogene imadenovec-drba) for the treatment of adults with recurrent respiratory papillomatosis (RRP). PAPZIMEOS is the first and only FDA-approved therapy for the treatment of adults with RRP. $HIND $TIVC $IVVD $PSTV $CODX $CSCI See More Pre-market Movers 👇 https://www.biopharmcatalyst.com/news/2025/precigen-pgen-fda-approval-plus-therapeutics-pstv-analyst https://www.biopharmcatalyst.com/news/2025/precigen-pgen-fda-approval-plus-therapeutics-pstv-analyst" [X Link](https://x.com/BPharmCatalyst/status/1956335126113099915) 2025-08-15T12:40Z 30.2K followers, [----] engagements "$IOBT reported a Q2 loss of $0.40 with cash of $28.1 million at June [--] [----] down from $60 million year-end and secured [----] million from EIB loan tranches in May and July extending runway into Q1 [----]. $PGEN $PSTV $HIND $CSCI $TIVC $IVVD $IOBT $CODX See More Biotech Updates👇 https://www.biopharmcatalyst.com/news/2025/precigen-pgen-59-approval-io-biotech-iobt-69-earnings https://www.biopharmcatalyst.com/news/2025/precigen-pgen-59-approval-io-biotech-iobt-69-earnings" [X Link](https://x.com/BPharmCatalyst/status/1956453443410817481) 2025-08-15T20:30Z 30.1K followers, [----] engagements "$APM and DiamiR Biosciences received approval from the NYSDOH to offer their APOE Genotyping test which helps assess Alzheimer's disease risk. Aptorum entered into a definitive agreement for an all-stock merger transaction to acquire DiamiR effective July [--] [----] making DiamiR a subsidiary of Aptorum. $IVVD $EVOK $NVAX $IMRX $SRPT $HIND See More Pre-market Movers 👇 https://www.biopharmcatalyst.com/news/2025/aptorum-group-apm-nysdoh-approval-evoke-pharma-evok-patent https://www.biopharmcatalyst.com/news/2025/aptorum-group-apm-nysdoh-approval-evoke-pharma-evok-patent" [X Link](https://x.com/BPharmCatalyst/status/1958509547439469038) 2025-08-21T12:40Z 30.1K followers, [----] engagements "$PTIX has completed the first dose injections for all subjects in the multiple-dose portion of its Phase [--] clinical trial for PT00114. This novel neuro-active peptide therapy derived from TCAP aims to modulate stress responses for treating various mental health conditions. Dosing is expected to conclude by August with topline safety data by September enabling progression to Phase [--] efficacy studies in Q1 [----]. $APM $PTIX $IVVD $EVOK $SRPT $NVAX $IMRX $HIND $THAR See More Biotech Updates👇" [X Link](https://x.com/BPharmCatalyst/status/1958627842029191540) 2025-08-21T20:30Z 30.3K followers, [----] engagements "$IXHL authorized a $20M share repurchase program allowing buybacks via open market private transactions or structured arrangements under Rule 10b5-1 and Rule 10b-18. $AZTR $APM $AEMD $EVOK $PTIX See More Pre-market Movers 👇 https://www.biopharmcatalyst.com/news/2025/incannex-ixhl-share-repurchase-program-azitra-aztr-reverse-split https://www.biopharmcatalyst.com/news/2025/incannex-ixhl-share-repurchase-program-azitra-aztr-reverse-split" [X Link](https://x.com/BPharmCatalyst/status/1958871839570100342) 2025-08-22T12:40Z 30.2K followers, [----] engagements "$IVVD shares are currently up during premarket hours after D. Boral Capital maintained a Buy rating on Invivyd and cut the price target to $1. $AIFF $SER $MRKR $IXHL $PSTV $EPIX $HCWB $VRAX $FEMY See More Pre-market Movers https://www.biopharmcatalyst.com/news/2025/invivyd-ivvd-analyst-firefly-aiff-clear-platform https://www.biopharmcatalyst.com/news/2025/invivyd-ivvd-analyst-firefly-aiff-clear-platform" [X Link](https://x.com/BPharmCatalyst/status/1960321391770640628) 2025-08-26T12:40Z 30.2K followers, [----] engagements "$CARM will receive a $5M private placement investment from $OCGN as part of its merger with Ocugen subsidiary OrthoCellix with terms ensuring Ocugen receives equal or better investor rights; the deal is contingent on shareholder and regulatory approvals" [X Link](https://x.com/BPharmCatalyst/status/1961541838042796364) 2025-08-29T21:29Z 30.1K followers, [----] engagements "BioPharmCatalyst Weekly #Watchlist Key Near-term Catalysts $AGIO $FBIO $SRRK $CRNX $INCY $MRK https://www.biopharmcatalyst.com/news/2025/biopharmcatalyst-weekly-watchlist-key-pdufa-dates-left-for-the-quarter https://www.biopharmcatalyst.com/news/2025/biopharmcatalyst-weekly-watchlist-key-pdufa-dates-left-for-the-quarter" [X Link](https://x.com/BPharmCatalyst/status/1961806114217160988) 2025-08-30T15:00Z 30.2K followers, [----] engagements "$UTHR reported its Phase [--] TETON-2 trial of nebulized Tyvaso in idiopathic pulmonary fibrosis met the primary endpoint with a [----] mL FVC improvement at [--] weeks (p0.0001) with significant benefits across multiple secondary measures and a favorable safety profile. $CARM $MLYS $IONS $HOTH $CYTK $IVA $ARWR See More Pre-market Movers https://www.biopharmcatalyst.com/news/2025/carisma-therapeutics-carm-private-placement-from-ocgn-united-therapeutics-uthr-phase-3-data" [X Link](https://x.com/BPharmCatalyst/status/1962858109983973672) 2025-09-02T12:40Z 30.2K followers, [----] engagements "$MLYS surged about 86% after AstraZeneca announced positive Phase [--] results for baxdrostat a blood pressure drug similar to Mineralys' lorundrostat. $CARM $WINT $TECX $UTHR $TNFA $MLYS $IONS $HOTH $CYTK $ $IVA $BRKR See More Biotech Updates👇 https://www.biopharmcatalyst.com/news/2025/carisma-carm-private-placement-mineralys-mlys-off-astrazeneca-azn-phase-3-data https://www.biopharmcatalyst.com/news/2025/carisma-carm-private-placement-mineralys-mlys-off-astrazeneca-azn-phase-3-data" [X Link](https://x.com/BPharmCatalyst/status/1962976431283032304) 2025-09-02T20:30Z 30.1K followers, [----] engagements "$INDP reported completion of the monotherapy arm in its INDP-D101 trial and initiation of seven patients in combination with tislelizumab noting one monotherapy patient previously treated with anti-PD-1 showed a partial response with liver metastasis shrinkage before progressing after four months. $ARTL $AEMD $PPBT $AGIO $SNY $NLSP $VANI $LGVN See More Biotech Updates👇 https://www.biopharmcatalyst.com/news/2025/artelo-biosciences-artl-public-offering-purple-biotech-ppbt-preclinical-data" [X Link](https://x.com/BPharmCatalyst/status/1963701210285818211) 2025-09-04T20:30Z 30.2K followers, [----] engagements "$AIFF announced a partnership with HealingMaps and Advanced Behavioral Strategies to integrate its FDA-cleared AI-driven EEG brain health platform. $BNTX $THAR $PMN $VANI $QURE $CERO See More Pre-market Movers https://www.biopharmcatalyst.com/news/2025/biontech-bntx-phase-3-data-cero-therapetics-cero-nasdaq-delisting-notice https://www.biopharmcatalyst.com/news/2025/biontech-bntx-phase-3-data-cero-therapetics-cero-nasdaq-delisting-notice" [X Link](https://x.com/BPharmCatalyst/status/1963945264089030758) 2025-09-05T12:40Z 30.2K followers, [----] engagements "$TRML will be acquired by $NVS for $48/share in cash valuing the deal at $1.4B and representing a 59% premium to the last close and 127% over the 60-day VWAP; the acquisition centers on Tourmalines lead asset pacibekatug targeting inflammation-driven cardiovascular disease and has been unanimously approved by both boards. $REVB $TELO $XLO $SLRX $ONCY $IONS See More Pre-market Movers https://www.biopharmcatalyst.com/news/2025/tourmaline-trml-acquired-by-nvs-revelation-biosciences-revb-phase-1b-data" [X Link](https://x.com/BPharmCatalyst/status/1965394833876394229) 2025-09-09T12:40Z 30.4K followers, [----] engagements "$ANEB updated its going-private process noting that it has received interest from potential partners and will review all strategic alternatives including a reverse stock split asset sale or merger. $HCWB $IFRX $GRI $COCP $MIRA $SMMT $ANEB $ADXN $TRVI $PROK See More Biotech Updates👇 https://www.biopharmcatalyst.com/news/2025/hcw-biologics-hcwb-68-data-anebulo-aneb-18-going-private https://www.biopharmcatalyst.com/news/2025/hcw-biologics-hcwb-68-data-anebulo-aneb-18-going-private" [X Link](https://x.com/BPharmCatalyst/status/1966600314464743936) 2025-09-12T20:30Z 30.3K followers, [----] engagements "$CHEK announced a merger with MBody AI an AI stack company. The combined entity to be renamed MBody AI Ltd. will be 90% owned by MBody AI and 10% by Check-Cap. The merger is also expected to synergize with Check-Caps Ghost Kitchen franchise rights in New Jersey. $CHEK $ATYR $GLUE $MESO $RCEL $COCP $SLRX $BIAF $ENTO $INDP $COCP See More Pre-market Movers https://www.biopharmcatalyst.com/news/2025/check-cap-chek-merger-with-mbody-ai-atyr-pharma-atyr-phase-3-fail https://www.biopharmcatalyst.com/news/2025/check-cap-chek-merger-with-mbody-ai-atyr-pharma-atyr-phase-3-fail" [X Link](https://x.com/BPharmCatalyst/status/1967569145500700796) 2025-09-15T12:40Z 30.2K followers, [----] engagements "$SILO has made initial purchases of Ethereum and Solana as part of its new cryptocurrency treasury strategy signaling a shift toward blockchain integration and real-world asset tokenization alongside its biopharma operations. $NAOV $SILO $DCTH $BIAF $CHEK $ATYR $ADAP $BVS $MTVA $TTNP See More Pre-market Movers https://www.biopharmcatalyst.com/news/2025/nanovibronix-naov-subsidiary-granted-patent-silo-pharma-silo-crypto-purchase https://www.biopharmcatalyst.com/news/2025/nanovibronix-naov-subsidiary-granted-patent-silo-pharma-silo-crypto-purchase" [X Link](https://x.com/BPharmCatalyst/status/1967931541197095066) 2025-09-16T12:40Z 30.4K followers, [----] engagements "$CODX signed an MoU with a Saudi partner to explore a joint venture that would license and commercialize its molecular diagnostics IP including the upcoming Co-Dx PCR point-of-care platform across the Middle East and North Africa expanding its model similar to its CoSara JV in India. $CODX $BNGO $KLRS $ENTO $HSDT $CHEK $WINT $ADAP $BCDA $ZBIO See More Biotech Updates👇 https://www.biopharmcatalyst.com/news/2025/co-diagnostics-codx-saudi-mou-agreement-bionano-genomics-bngo-offering https://www.biopharmcatalyst.com/news/2025/co-diagnostics-codx-saudi-mou-agreement-bionano-genomics-bngo-offering" [X Link](https://x.com/BPharmCatalyst/status/1968049934038376917) 2025-09-16T20:30Z 30.2K followers, [----] engagements "$SPRC shares traded higher after AutoMax filed a court motion regarding its merger with a judge granting a stay due to deal uncertainties. AutoMax requested the stay because of potential difficulties meeting closing conditions amid recent business developments according to a filing. $SPRC $CDT $CODX $VANI $ENVB $BIAF $SHPH $SABS $CURX $MTVA See More Biotech Updates👇 https://www.biopharmcatalyst.com/news/2025/scisparc-sprc-judge-granted-stay-cdt-equity-cdt-crypto https://www.biopharmcatalyst.com/news/2025/scisparc-sprc-judge-granted-stay-cdt-equity-cdt-crypto" [X Link](https://x.com/BPharmCatalyst/status/1968412353705230570) 2025-09-17T20:30Z 30.2K followers, [----] engagements "$REPL said it completed a Type A meeting with the FDA regarding the CRL for its BLA of RP1 plus nivolumab in advanced melanoma with no clear accelerated approval path yet established as the company reviews agency feedback and next steps. $ETNB $REPL $JSPR $RVPH $APVO $BCDA $ADAP $PBM $CDT $SLRX See More Biotech Updates👇 https://www.biopharmcatalyst.com/news/2025/roche-rhhby-acquires-89bio-etnb-replimune-repl-type-a-meeting https://www.biopharmcatalyst.com/news/2025/roche-rhhby-acquires-89bio-etnb-replimune-repl-type-a-meeting" [X Link](https://x.com/BPharmCatalyst/status/1968774814316773643) 2025-09-18T20:31Z 30.3K followers, [----] engagements "$RVPH priced a public offering of 27M shares and accompanying Series E and F warrants at $0.335 per share raising approximately $9M in gross proceeds to support its late-stage CNS inflammatory and cardiometabolic drug pipeline. $RVPH $VRCA $JSPR $BFLY $IMNN $CMND $CLLS $DVAX $ARTL $APVO See More Pre-market Movers https://www.biopharmcatalyst.com/news/2025/reviva-rvph-9m-offering-verrica-pharmaceuticals-vrca-japanese-approval https://www.biopharmcatalyst.com/news/2025/reviva-rvph-9m-offering-verrica-pharmaceuticals-vrca-japanese-approval" [X Link](https://x.com/BPharmCatalyst/status/1969018698116579666) 2025-09-19T12:40Z 30.3K followers, [----] engagements "$ANAB plans to split into two public entities by 2026: a royalty-focused firm managing high-value assets like GSK's Jemperli royalties and Vanda milestones and a biopharma progressing rosnilimab (RA UC) ANB033 and ANB101 in immunology. The aim is to unlock value align strategies and enable independent growth. SAN The company will also host a virtual event on October [--] about ANB033 its CD122 antagonist. $SPRC $ANAB $SCYX $KALA $APDN $ARTL $ZURA $CASI $GOVX $ENTA See More Biotech Updates👇 https://www.biopharmcatalyst.com/news/2025/scisparc-sprc-35-acquisition-anaptysbio-anab-32-strategic-plan" [X Link](https://x.com/BPharmCatalyst/status/1973123477663031488) 2025-09-30T20:31Z 30.3K followers, [----] engagements "$GNPX announced preclinical data showing its lead candidate Reqorsa (quaratusugene ozeplasmid) induced apoptosis and demonstrated strong efficacy in ALK-EML4positive non-small cell lung cancer models. The data to be presented at the AACR-NCI-EORTC Molecular Targets Conference support Reqorsas potential as a gene therapy targeting the TUSC2 tumor suppressor pathway and its use in combination with ALK inhibitors. $GNPX $SCYX $KROS $EYPT $SPRC $EVAX $DMAC $IOBT $ELAB $ENTX See More Pre-market Movers" [X Link](https://x.com/BPharmCatalyst/status/1978440788246724827) 2025-10-15T12:40Z 30.4K followers, 12.5K engagements "$AVII filing out. S/holder vote 7/10 to change company name to Sarepta Therapeutics Inc $SRPT + voting for 1-for-4 to 1-for-6 reverse split" [X Link](https://x.com/BPharmCatalyst/status/208674126733385728) 2012-06-01T21:39Z 28.9K followers, [--] engagements "BioPharmCatalyst updates: $VTUS fails Ph3. $MAPP refile NDA 3Q/4Q. $CYTR Ph2b data '13 + $LXRX $CUR $RPTP http://t.co/DZioFGkB http://bit.ly/MRLmnZ http://bit.ly/MRLmnZ" [X Link](https://x.com/BPharmCatalyst/status/217574225991577601) 2012-06-26T11:05Z 29.9K followers, [--] engagements "BioPharmCatalyst updates: $NVO terminate $PCRX agreement. $OSUR FDA approval $CHTP additional trial + $MNOV $PTN $SPPI http://t.co/AApsGeqO http://bit.ly/KROvAx http://bit.ly/KROvAx" [X Link](https://x.com/BPharmCatalyst/status/220254620843380737) 2012-07-03T20:36Z 28.9K followers, [--] engagements "BioPharmCatalyst updates: $CRTX Adcom set. $MAPP NDA update + updates for $ZGNX $ITMN $MDVN $AEZS $DVAX $NKTR $CADX http://t.co/HAA4wZzu http://bit.ly/O7WqQi http://bit.ly/O7WqQi" [X Link](https://x.com/BPharmCatalyst/status/228085747901665281) 2012-07-25T11:14Z 29.8K followers, [--] engagements "BioPharmCatalyst updates $MAPP PDUFA set. $SPPI files shelf http://t.co/ZsJ9zx6O Other catalysts check the FDA Calendar http://t.co/r4AynIX6 http://bit.ly/w1b1aF http://bit.ly/QbENjL http://bit.ly/w1b1aF http://bit.ly/QbENjL" [X Link](https://x.com/BPharmCatalyst/status/271445257529458688) 2012-11-22T02:49Z 29.8K followers, [--] engagements "BioPharmCatalyst updates: http://t.co/n0yCGNcm $DCTH on track for May Adcom. $BLRX data Mar+ $ALNY $CLVS$ INFI $OREX $FOLD $ICPT http://bit.ly/WGpg9D http://bit.ly/WGpg9D" [X Link](https://x.com/BPharmCatalyst/status/288497992611291137) 2013-01-08T04:10Z 28.9K followers, [--] engagements "BPC Updates http://t.co/gUIXB31lSq $AFFY $QLTI $RPRX $CRIS $CHTP $CELG $AEZS $ONCY $ACHN $GTXI $CLSN $SYN $IMMU $VVUS $GENT $ITMN $NPSP IMGN http://bit.ly/X567RM http://bit.ly/X567RM" [X Link](https://x.com/BPharmCatalyst/status/305734911816519680) 2013-02-24T17:44Z 28.9K followers, [--] engagements "BioPharmCatalyst updates: $ARRY $ALNY $CELG $ISIS $ENTA $CYTR http://t.co/0xGaQ61H0T http://bit.ly/YCeWXn http://bit.ly/YCeWXn" [X Link](https://x.com/BPharmCatalyst/status/331726317894643713) 2013-05-07T11:04Z 28.9K followers, [--] engagements "BioPharmCatalyst updates: $CELG $BMRN $RCPT $OPK $BMRN $IDRA $ZGNX $MELA http://t.co/pLWR5dO8QR http://www.biopharmcatalyst.com/June5update http://www.biopharmcatalyst.com/June5update" [X Link](https://x.com/BPharmCatalyst/status/342602296393351168) 2013-06-06T11:22Z 28.9K followers, [--] engagements "BioPharmCatalyst updates: $MNKD Adcom set. $BDSI Ph3 data due Jan/Feb + $ATHX $BOTA $ALNY $RIGL $STEM http://t.co/MLCMnHKNqc http://www.biopharmcatalyst.com/jan10updates http://www.biopharmcatalyst.com/jan10updates" [X Link](https://x.com/BPharmCatalyst/status/422160827697741824) 2014-01-12T00:19Z 28.9K followers, [--] engagements "RT @chasingthealpha: just donated $10 to www.biopharmcatalyst.com/ great site great catalyst tracker/calendar thats FREE Thanks as always" [X Link](https://x.com/BPharmCatalyst/status/43373690372624384) 2011-03-03T18:14Z 28.9K followers, [--] engagements "BioPharmCatalyst updates: $NBIX Ph3 data due Jan + other catalyst dates for $ALDR $MCUR $THLD http://t.co/khFlkG7lDl http://www.biopharmcatalyst.com/Nov3BiotechNews http://www.biopharmcatalyst.com/Nov3BiotechNews" [X Link](https://x.com/BPharmCatalyst/status/529615337583431681) 2014-11-04T12:45Z 28.9K followers, [--] engagements "BioPharmCatalyst updates: Updates for $BDSI $BLUE $DVAX $INCY $MEIP $TGTX $IRWD http://t.co/IGiSBYMXNU http://www.biopharmcatalyst.com/LatestPipelineUpdates http://www.biopharmcatalyst.com/LatestPipelineUpdates" [X Link](https://x.com/BPharmCatalyst/status/542661316461096961) 2014-12-10T12:45Z 28.9K followers, [--] engagements "BioPharmCatalyst Pipeline updates for $ALKS $ARDX $BMRN $CEMP $EXEL $FLXN $INFI $NKTR $XOMA + more http://t.co/kEbfG0TnMl http://www.biopharmcatalyst.com/Feb24-25BiotechUpdates http://www.biopharmcatalyst.com/Feb24-25BiotechUpdates" [X Link](https://x.com/BPharmCatalyst/status/570927568351666177) 2015-02-26T12:45Z 28.9K followers, [--] engagements "BioPharmCatalyst updates: $INCY $SGEN $BMRN $CEMP $CYTK CYTR $EBIO $EXEL $LXRX $MDCO $NBIX THLD THRX TSRO + more http://t.co/ZzM188O5e5 http://www.biopharmcatalyst.com/May1EndofWeekUpdates http://www.biopharmcatalyst.com/May1EndofWeekUpdates" [X Link](https://x.com/BPharmCatalyst/status/594625542042693633) 2015-05-02T22:12Z 28.9K followers, [--] engagements "Vry late+doubt anyone up but latest updates $EPCT $VVUS $NBIX $EXEL $MAPP $ALXA $NEOP $LXRX $NPSP $INCY http://bit.ly/m5Nkxu" [X Link](https://x.com/BPharmCatalyst/status/65691787670458368) 2011-05-04T08:18Z 28.9K followers, [--] engagements "BioPharmCatalyst updates: $EXEL #PDUFA set for June [--]. $RIGL Ph3 data due mid year + $CORT $NBIX http://www.biopharmcatalyst.com/Jan28UpdatesBPC http://www.biopharmcatalyst.com/Jan28UpdatesBPC" [X Link](https://x.com/BPharmCatalyst/status/693040676246654976) 2016-01-29T11:59Z 28.9K followers, [--] engagements "BioPharmCatalyst updates: $ALNY completes Ph3 APOLLO enrollment+ $ARIA $CBYL $DSCO $REPH $TENX $TTHI http://www.biopharmcatalyst.com/Feb1UpdatesBPC http://www.biopharmcatalyst.com/Feb1UpdatesBPC" [X Link](https://x.com/BPharmCatalyst/status/694490221681872896) 2016-02-02T11:59Z 28.9K followers, [--] engagements "BioPharmCatalyst updates: $BNHLF expected CRL. $SYN Ph2 trial fail. $ARRY Phase [--] data due [----] + $MDWD $NBIX $HSGX http://www.biopharmcatalyst.com/2016/02/bnhlf-receives-expected-crl-syn-phase-2-trial-fail-arry-phase-3-data-due-2016-mdwd-nbix-hsgx-updates/ http://www.biopharmcatalyst.com/2016/02/bnhlf-receives-expected-crl-syn-phase-2-trial-fail-arry-phase-3-data-due-2016-mdwd-nbix-hsgx-updates/" [X Link](https://x.com/BPharmCatalyst/status/694852611736928258) 2016-02-03T11:59Z 28.9K followers, [--] engagements "BioPharmCatalyst updates: $FLML FDA Approval + $ADRO $ALNY $ARGS $CEMP $CERU $GNVC $MACK $MCRB $NWBO $MCRB + more http://www.biopharmcatalyst.com/2016/05/flml-fda-approval-updates-for-adro-alny-args-cemp-ceru-flml-gnvc-mack-mcrb-mrns-nwbo-prtk-rgls-tbra-tnxp-trvn-xncr/ http://www.biopharmcatalyst.com/2016/05/flml-fda-approval-updates-for-adro-alny-args-cemp-ceru-flml-gnvc-mack-mcrb-mrns-nwbo-prtk-rgls-tbra-tnxp-trvn-xncr/" [X Link](https://x.com/BPharmCatalyst/status/727452427759185920) 2016-05-03T10:59Z 28.9K followers, [--] engagements "ICYMI: [--] Biotech Stocks to put on your Watchlist: $DPRX $DRRX $GNCA $KITE $MSTX $OPHT $OPXA $PTIE $PTN $VRTX http://biopharmcatalyst.com/news/2016/biotech-stock-watchlist-for-week-commencing-september-19 http://biopharmcatalyst.com/news/2016/biotech-stock-watchlist-for-week-commencing-september-19" [X Link](https://x.com/BPharmCatalyst/status/777598160440995847) 2016-09-18T20:00Z 28.9K followers, [--] engagements "Biotech Watchlist 9/26 $ANTH $DPRX $DRRX $GNCA $KITE $MRNS $OPHT $PTN $VRTX +NASH runners $BLRX $GALT $CNAT $GLMD http://biopharmcatalyst.com/news/2016/biotech-stock-watchlist-for-week-of-september-26-2016 http://biopharmcatalyst.com/news/2016/biotech-stock-watchlist-for-week-of-september-26-2016" [X Link](https://x.com/BPharmCatalyst/status/779666867963080704) 2016-09-24T13:00Z 28.9K followers, [--] engagements "BPC Week in Review + Jan Event Watch List $DMTX HemB $FGEN Panc+Ph3 China Jan/Feb $NBIX Ph2 $SGYP PDUFA $TENX Ph3 http://biopharmcatalyst.com/news/2017/biopharmcatalyst-expands-coverage-biotech-week-in-review-six-upcoming-january-catalysts http://biopharmcatalyst.com/news/2017/biopharmcatalyst-expands-coverage-biotech-week-in-review-six-upcoming-january-catalysts" [X Link](https://x.com/BPharmCatalyst/status/820276787137507329) 2017-01-14T14:30Z 28.9K followers, [--] engagements "Biotech Movers 04/26 $AKBA $FLKS $BPMX $FLXN offerings Pipeline updates $ABIO $AZN ARTIC delay $JAZZ $ALNY $RARX https://biopharmcatalyst.com/news/2017/flexion-flxn-slumps-on-notes-offering-akebia-akba-maintains-upward-momentum https://biopharmcatalyst.com/news/2017/flexion-flxn-slumps-on-notes-offering-akebia-akba-maintains-upward-momentum" [X Link](https://x.com/BPharmCatalyst/status/857384248667275265) 2017-04-27T00:01Z 28.9K followers, [--] engagements "Biotech Wk in Review 5/19+ Upcoming non-ASCO catalysts for: $AZN $ALDR $ALNY $BLUE $CARA $MTNB $NVS $PBYI $PTLA https://www.biopharmcatalyst.com/news/2017/upcoming-non-asco-biotech-stock-catalysts-biotech-week-in-review-may-19-2017 https://www.biopharmcatalyst.com/news/2017/upcoming-non-asco-biotech-stock-catalysts-biotech-week-in-review-may-19-2017" [X Link](https://x.com/BPharmCatalyst/status/866080174709682176) 2017-05-20T23:56Z 28.9K followers, [--] engagements "Biotech Review+ [--] catalysts left for Sept $ABUS/ $ALNY $AXON $BCRX $FCSC $FOLD $NBRV $PRQR $PTCT $RDHL $VSAR $ZGNX https://www.biopharmcatalyst.com/news/2017/12-biotech-catalysts-to-round-out-september-biotech-week-in-review-september-15-2017 https://www.biopharmcatalyst.com/news/2017/12-biotech-catalysts-to-round-out-september-biotech-week-in-review-september-15-2017" [X Link](https://x.com/BPharmCatalyst/status/908788539172691968) 2017-09-15T20:24Z 28.9K followers, [--] engagements "Biotech Wk in Review 9/29+ upcoming biotech events- early Oct: $ACRX $AERI $CAPR $FENC $FOLD $FLXN $ONCE $RDHL $SRPT https://www.biopharmcatalyst.com/news/2017/10-biotech-events-for-the-first-two-weeks-of-october-2017-week-in-review-09-29-2017 https://www.biopharmcatalyst.com/news/2017/10-biotech-events-for-the-first-two-weeks-of-october-2017-week-in-review-09-29-2017" [X Link](https://x.com/BPharmCatalyst/status/914272745088729088) 2017-09-30T23:36Z 28.9K followers, [--] engagements "@libraryinvestor Potentially something to add for BPC looking 6-12 months ahead.can imagine that it would be $pricey to set up though" [X Link](https://x.com/BPharmCatalyst/status/915362494582890496) 2017-10-03T23:46Z 29.9K followers, [--] engagements "11/2 AH Pipeline Updates added: $ABUS $APRI $AXON $CALA $CARA $CRVS $MYOK $RARE $RDUS $RVNC $SPPI $VRX $VYGR https://x.com/crusadernz/status/926239060187738112 https://www.biopharmcatalyst.com/news/2017/ocera-ocrx-72-on-acquisition-alnylam-alny-10-on-positive-attr-data Biotech updates 11/2 $OCRX buyout +72% $ALNY +ve ATTR data $IONS + $KPTI $PGNX $SAGE $SGEN $SNSS $TRVN $VRX + more https://t.co/L1TVHzfY8J https://x.com/crusadernz/status/926239060187738112 https://www.biopharmcatalyst.com/news/2017/ocera-ocrx-72-on-acquisition-alnylam-alny-10-on-positive-attr-data Biotech updates 11/2 $OCRX" [X Link](https://x.com/BPharmCatalyst/status/926387305572474881) 2017-11-03T09:55Z 28.9K followers, [--] engagements "$ALNY files mixed shelf $150m. Filing - http://bit.ly/rovbOZ" [X Link](https://x.com/BPharmCatalyst/status/94146305370234880) 2011-07-21T20:46Z 28.9K followers, [--] engagements "Upcoming 1Q [----] PDUFA and Advisory Committee dates; Biotech Wk in Review 12/22: $ARDM $APRI $GILD $LLY $LPCN $KMPH $OTIC $PCRX $SGYP $VRTX https://www.biopharmcatalyst.com/news/2017/pdufa-and-advisory-committee-meeting-dates-for-1q-2018-biotech-stock-week-in-review https://www.biopharmcatalyst.com/news/2017/pdufa-and-advisory-committee-meeting-dates-for-1q-2018-biotech-stock-week-in-review" [X Link](https://x.com/BPharmCatalyst/status/945024055882559488) 2017-12-24T20:11Z 28.9K followers, [--] engagements "Biotech Updates 1/31: $CASC acquired by $SGEN $VRTX to proceed Ph3 CF triple $ALKS files depression NDA $SAGE promising insomnia data $ONCS offering + $BGNE $CARA $CBIO $DERM $GEMP $JNP $LLY $MNOV $ZGNX https://www.biopharmcatalyst.com/news/2018/cascadian-casc-soar-71-on-acquisition-by-seattle-genetics-sgen-vertex-vrtx-to-proceed-with-phase-3-cf-triple-regimen https://www.biopharmcatalyst.com/news/2018/cascadian-casc-soar-71-on-acquisition-by-seattle-genetics-sgen-vertex-vrtx-to-proceed-with-phase-3-cf-triple-regimen" [X Link](https://x.com/BPharmCatalyst/status/958868209221885952) 2018-02-01T01:02Z 28.9K followers, [--] engagements "Biotech Updates 02/01: $ALNY patisiran PDUFA 8/11 $SLGO IPO pipeline added $ICPT Ocaliva label update $AGN AVYCAZ sNDA approval $AFMD +40% lymphoma data + $AMGN $CYAD $IMRN updates. https://www.biopharmcatalyst.com/news/2018/intercept-icpt-announces-ocaliva-label-update-affimed-afmd-shares-up-on-updated-lymphoma-data https://www.biopharmcatalyst.com/news/2018/intercept-icpt-announces-ocaliva-label-update-affimed-afmd-shares-up-on-updated-lymphoma-data" [X Link](https://x.com/BPharmCatalyst/status/959211382456467456) 2018-02-01T23:46Z 28.9K followers, [--] engagements "Biotech Updates 2/8: $TEVA -11% on warning letter $GEMP -28% on offering $JNJ ZYTIGA prostate approval $RNN discontinues RCC $MDGL meets endpoint but -10% + $ABEO $ALNY $ALXN $MEIP pipeline updates https://www.biopharmcatalyst.com/news/2018/teva-shares-slip-on-likely-regulatory-delay https://www.biopharmcatalyst.com/news/2018/teva-shares-slip-on-likely-regulatory-delay" [X Link](https://x.com/BPharmCatalyst/status/961784540971679744) 2018-02-09T02:11Z 28.9K followers, [--] engagements "Biotech Events left slated for Feb + Week in Review: $AMAG / $ATRS $AIMT $APRI $KDMN $KMPH $KURA $MRNS $NVAX $PCRX $SRNE $VRTX https://www.biopharmcatalyst.com/news/2018/11-upcoming-biotech-stock-events-slated-for-february-biotech-week-in-review https://www.biopharmcatalyst.com/news/2018/11-upcoming-biotech-stock-events-slated-for-february-biotech-week-in-review" [X Link](https://x.com/BPharmCatalyst/status/962456377019973632) 2018-02-10T22:40Z 28.9K followers, [--] engagements "Biotech updates 02/12/2018: $AXON CEO resigns -20% $VRTX CF approval $DARE +50% license deal $FOLD PDUFA Aug [--] $KDMN +21% $CBIO $AFMD offerings https://www.biopharmcatalyst.com/news/2018/axovant-axon-ceo-resigns-shares-20-vertex-vtrx-cf-approval-dare-50-on-license-agreement https://www.biopharmcatalyst.com/news/2018/axovant-axon-ceo-resigns-shares-20-vertex-vtrx-cf-approval-dare-50-on-license-agreement" [X Link](https://x.com/BPharmCatalyst/status/963224447673970693) 2018-02-13T01:32Z 28.9K followers, [--] engagements "Biotech updates 2/14: $BIIB -7% Alzheimer's update $NKTR p/ship $BMY $AMAG $ATRS approval $AMGN BLINCYTO Adcom 3/7; $GLMD fail -42% $CDMO $FOLD offerings $VRX PDUFA 10/5 + $ATNX $AGIO $ALKS $ICPT $MYOK $NBIX $PRTA $SNNA $VNDA $VRTX https://www.biopharmcatalyst.com/news/2018/nektar-nktr-seals-partnership-with-bristol-myers-bmy-galmed-glmd-shares-slide-on-mid-stage-trial-fail https://www.biopharmcatalyst.com/news/2018/nektar-nktr-seals-partnership-with-bristol-myers-bmy-galmed-glmd-shares-slide-on-mid-stage-trial-fail" [X Link](https://x.com/BPharmCatalyst/status/963947797463494656) 2018-02-15T01:27Z 28.9K followers, [--] engagements "Upcoming key Phase [--] Biotech Catalysts left for 1Q + wk in Review: $AIMT $ANTH $BHVN $CLSD $DERM $ESPR $GWPH $IMGN $NBIX $NRBV (spring) $REGN $VBLT $VTVT https://www.biopharmcatalyst.com/news/2018/phase-3-biotech-catalysts-to-watch-1q-2018-biotech-week-in-review https://www.biopharmcatalyst.com/news/2018/phase-3-biotech-catalysts-to-watch-1q-2018-biotech-week-in-review" [X Link](https://x.com/BPharmCatalyst/status/964834968038866946) 2018-02-17T12:12Z 28.9K followers, [--] engagements "Biotech Updates 2/21: $ABBV $NBIX +ve data $ANTH +44% on Roth PT $10 $GWPH Ph2 fail + Adcom 4/19 $DVAX ACIP approval + $ATOS $NERV $BLUE $GWPH pipeline updates https://www.biopharmcatalyst.com/news/2018/abbvie-abbv-neurocrine-nbix-late-stage-positive-data https://www.biopharmcatalyst.com/news/2018/abbvie-abbv-neurocrine-nbix-late-stage-positive-data" [X Link](https://x.com/BPharmCatalyst/status/966479350827646976) 2018-02-22T01:06Z 28.9K followers, [--] engagements "Dec catalysts Pt2: Ph3 data $VVUS $CORT $INCY Ph2 data $CAPS $CYCC $IMMU $CYTK $INHX $VPHM. Calendar - http://bit.ly/aiki0d" [X Link](https://x.com/BPharmCatalyst/status/9672362614071296) 2010-11-30T18:17Z 28.9K followers, [--] engagements "11 PDUFA and Advisory Committee Meeting dates for March and April (small/mid-cap) + Biotech Wk in Review $CLVS $GWPH $MNK $NBIX $OTIC $PCRX $PGNX $RARE $RIGL $SRNE (2/28) $THERF https://www.biopharmcatalyst.com/news/2018/11-pdufa-and-advisory-committee-meeting-dates-for-march-and-april-small-and-mid-cap https://www.biopharmcatalyst.com/news/2018/11-pdufa-and-advisory-committee-meeting-dates-for-march-and-april-small-and-mid-cap" [X Link](https://x.com/BPharmCatalyst/status/967515054047248384) 2018-02-24T21:42Z 29.8K followers, [--] engagements "Biotech Updates 02/28: $SRNE FDA Approval $ECYT +41% $AGN PDUFA delayed till August $ACAD $TSRO $VRX slide on earnings $CORI offering + updates for $BCRX $CANF $CMTA $MBVX $TCON $HTBX $NVAX https://www.biopharmcatalyst.com/news/2018/sorrento-srne-18-on-fda-approval-endocyte-ecyt-41-on-positive-offering https://www.biopharmcatalyst.com/news/2018/sorrento-srne-18-on-fda-approval-endocyte-ecyt-41-on-positive-offering" [X Link](https://x.com/BPharmCatalyst/status/968985351430664192) 2018-02-28T23:04Z 29.8K followers, [--] engagements "Biotech Stock Updates 3/6: $THERF FDA Approval +30% $BMY Approval $CLSD offering $PLX data March $RIGL data+PDUFA April $GLYC -18% + $AGLE $ALNA $BHVN $BIVV $BLRX $CTXR $RGNX $ZFGN $ZGNX updates https://www.biopharmcatalyst.com/news/2018/theratechnologies-therf-fda-approval-marinus-mrns-14-on-data-delay https://www.biopharmcatalyst.com/news/2018/theratechnologies-therf-fda-approval-marinus-mrns-14-on-data-delay" [X Link](https://x.com/BPharmCatalyst/status/971190483480297472) 2018-03-07T01:07Z 29.8K followers, [--] engagements "10 Biotech Stock Events to round out 1Q 2018; Biotech Stock Week in Review $ALT $ANAB $ARMO $BHVN $CDTX $CLLS $FLKS $IMGN $PTGX $TSRO https://www.biopharmcatalyst.com/news/2018/biotech-stock-events-to-round-out-1q-2018-biotech-stock-week-in-review https://www.biopharmcatalyst.com/news/2018/biotech-stock-events-to-round-out-1q-2018-biotech-stock-week-in-review" [X Link](https://x.com/BPharmCatalyst/status/974982060300410881) 2018-03-17T12:13Z 29.9K followers, [--] engagements "Biotech updates 03/19: Data out for $HRTX +27% $ARNA +25% $CDTX -24% $PSDV PDUFA 11/5 $PTIE Adcom 6/26 Offerings $PTI $GLYC $XNCR Pipeline updates for $LIFE $AGIO $BYSI $DNLI $FCSC $MDWD https://www.biopharmcatalyst.com/news/2018/heron-hrtx-27-and-arena-arna-23-surge-on-data https://www.biopharmcatalyst.com/news/2018/heron-hrtx-27-and-arena-arna-23-surge-on-data" [X Link](https://x.com/BPharmCatalyst/status/975871054898868224) 2018-03-19T23:06Z 29.8K followers, [--] engagements "Upcoming Biotech Catalysts for April + Wk in Review: $GWPH $IMGN $INCY $KPTI $NBRV $PCRX $PFSCF $RARE $RIGL $SELB $VTVT (+ March $ANAB $BHVN ) https://www.biopharmcatalyst.com/news/2018/upcoming-biotech-stock-catalysts-for-april-biotech-week-in-review https://www.biopharmcatalyst.com/news/2018/upcoming-biotech-stock-catalysts-for-april-biotech-week-in-review" [X Link](https://x.com/BPharmCatalyst/status/977550855770656770) 2018-03-24T14:21Z 29.8K followers, [--] engagements "Biotech Stock Updates 3/29: Offerings $ZSAN -45% $PULM -31% $INSM $CPRX NDA filings $MNOV fail -15% $PFE data $ALNY -9% $AKCA -13% + $AKTX $ARMO $GALT pipeline updates. https://www.biopharmcatalyst.com/news/2018/zosano-zsan-slides-on-offering-45-medicinova-mnov-fails-mid-stage-trial-15 https://www.biopharmcatalyst.com/news/2018/zosano-zsan-slides-on-offering-45-medicinova-mnov-fails-mid-stage-trial-15" [X Link](https://x.com/BPharmCatalyst/status/979499125858185217) 2018-03-29T23:22Z 29.9K followers, [--] engagements "Upcoming Regulatory Dates in April/May: PDUFA dates: $DOVA $KTOV $LPCN $RARE $REPH $RIGL $TXMD $VRX; Advisory Committee: $AKCA $AKAO $GWPH $INCY $INSY $SIGA https://www.biopharmcatalyst.com/news/2018/upcoming-pdufa-dates-and-advisory-committee-meetings-for-april-may https://www.biopharmcatalyst.com/news/2018/upcoming-pdufa-dates-and-advisory-committee-meetings-for-april-may" [X Link](https://x.com/BPharmCatalyst/status/985139361770622981) 2018-04-14T12:55Z 28.9K followers, [--] engagements "Biotech Stock Updates 04/17: $RIGL $RARE FDA Approval $GWPH +ve Adcom notes +11% $NVCR +8% $APLS -17% offering + Pipeline updates for $RCUS $PTI $VBIV https://www.biopharmcatalyst.com/news/2018/fda-awards-approval-to-both-rigel-rigl-and-ultragenyx-rare-gwph-receives-boost-heading-into-advisory-committee-meeting https://www.biopharmcatalyst.com/news/2018/fda-awards-approval-to-both-rigel-rigl-and-ultragenyx-rare-gwph-receives-boost-heading-into-advisory-committee-meeting" [X Link](https://x.com/BPharmCatalyst/status/986394212160581632) 2018-04-18T00:01Z 28.9K followers, [--] engagements "Biotech Updates 04/25: $ACAD -22% CNN report $DARE +57% $ABBV files Psoriasis BLA $SNY flu PDUFA 1/28 ASCO abstract titles out - Pipeline updates $ARMO $AVXS $BMRN $CALA $CANF $CNCE $DCPH https://www.biopharmcatalyst.com/news/2018/acadia-acad-shares-22-on-cnn-report-asco-2018-abstract-titles-out https://iplanner.asco.org/am2018/ https://www.biopharmcatalyst.com/news/2018/acadia-acad-shares-22-on-cnn-report-asco-2018-abstract-titles-out https://iplanner.asco.org/am2018/" [X Link](https://x.com/BPharmCatalyst/status/989294267980857344) 2018-04-26T00:05Z 29.9K followers, [--] engagements "Biotech stock updates 04/30: $KPTI +25% on STORM data $STDY acquired +77% $AZRX offering $NVS Tafinlar approval $REGN $SNY cemiplimab PDUFA 10/28 $MRK KEYNOTE-189 PDUFA 9/23 + Pipeline updates for $AGN $BOLD $CNAT $GNCA $NBIX $NKTR $QURE $RCKT $VYGR $ABLX" [X Link](https://x.com/BPharmCatalyst/status/991088174406369280) 2018-04-30T22:53Z 29.9K followers, [--] engagements "Biotech Stock Events on watch for May; Biotech Week in Review Data: $BOLD $EBIO $JNJ $BMRN $URGN $NBRV $RCKT $MDGL PDUFA/Adcom; $AKCA $INSY $DOVA $REPH $KTOV $TXMD $LPCN https://www.biopharmcatalyst.com/news/2018/biotech-stock-catalysts-on-watch-for-may-biotech-week-in-review https://www.biopharmcatalyst.com/news/2018/biotech-stock-catalysts-on-watch-for-may-biotech-week-in-review" [X Link](https://x.com/BPharmCatalyst/status/992762012559028224) 2018-05-05T13:44Z 28.9K followers, [--] engagements "Biotech Updates 05/10: $ARMO +67% $LLY buyout $AKCA $IONS +ve Adcom vote $RHHBY $EXEL IMblaze fail + wrap of 1Q earnings pipeline updates https://www.biopharmcatalyst.com/news/2018/armo-shares-67-on-acquisition-akcea-akca-and-ionis-ions-score-positive-vote-by-fda-panel-exelixis-exel-14-on-late-stage-fail https://www.biopharmcatalyst.com/news/2018/armo-shares-67-on-acquisition-akcea-akca-and-ionis-ions-score-positive-vote-by-fda-panel-exelixis-exel-14-on-late-stage-fail" [X Link](https://x.com/BPharmCatalyst/status/994770033476866048) 2018-05-11T02:43Z 29.9K followers, [--] engagements "15 PDUFA/Advisory Committee dates slated for May/June: $AKAO $AMGN $ARRY $BMRN $DERM $DOVA $DRRX $GWPH $INCY $INSY $KTOV $LLY $PTIE $REPH $SCPH $TXMD $VRX https://www.biopharmcatalyst.com/news/2018/15-advisory-committee-and-pdufa-dates-slated-for-may-and-june-biotech-week-in-review https://www.biopharmcatalyst.com/news/2018/15-advisory-committee-and-pdufa-dates-slated-for-may-and-june-biotech-week-in-review" [X Link](https://x.com/BPharmCatalyst/status/995657418133639168) 2018-05-13T13:30Z 28.9K followers, [--] engagements Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing
@BPharmCatalyst BioPharmCatalyst
BioPharmCatalyst posts on X about strong, $incy, $qncx, $fold the most. They currently have [------] followers and [---] posts still getting attention that total [-----] engagements in the last [--] hours.
Engagements: [-----] #
- [--] Week [------] -40%
- [--] Month [------] +81%
- [--] Months [-------] -73%
- [--] Year [---------] -51%
Mentions: [--] #
- [--] Week [--] -24%
- [--] Month [--] +33%
- [--] Months [---] -11%
- [--] Year [---] +1.40%
Followers: [------] #
- [--] Week [------] +0.01%
- [--] Month [------] +0.25%
- [--] Months [------] +2.40%
- [--] Year [------] +5%
CreatorRank: [-------] #
Social Influence
Social category influence stocks 67.36% cryptocurrencies 28.47% finance 22.22% countries 2.78% technology brands 1.39% currencies 1.39% exchanges 0.69%
Social topic influence strong #2460, $incy 5.56%, $qncx #14, $fold 4.86%, $wint 4.86%, $srpt 4.86%, events 4.86%, $clsd 4.17%, $slrx 4.17%, acquisition 4.17%
Top accounts mentioned or mentioned by @mwb741 @yusufhameed @chasingthealpha @libraryinvestor @auditor112017 @markmarkuu @grok
Top assets mentioned Incyte Corporation (INCY) Amicus Therapeutics, Inc (FOLD) Sarepta Therapeutics, Inc. (SRPT) Eli Lilly and Company (LLY) BioMarin Pharmaceutical, Inc. (BMRN) Cytokinetics Inc. (CYTK) IO Biotech, Inc. (IOBT) apM Coin (APM) Ionis Pharmaceuticals, Inc. Common Stock (IONS) Exelixis Inc (EXEL) Contineum Therapeutics, Inc (CTNM) Novavax Inc (NVAX) Anebulo Pharmaceuticals, Inc. (ANEB) CheckDot (CDT) Evotec SE (EVO) Invivyd, Inc. (IVVD) Agios Pharmaceuticals, Inc. (AGIO) Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Elevai Labs, Inc. (ELAB) ADiTx Therapeutics, Inc. (ADTX) LYRA (LYRA) Abivax SA (ABVX) Shuttle Pharmaceuticals Holdings, Inc. (SHPH) Denali Therapeutics Inc. Common Stock (DNLI) Rallybio Corporation (RLYB) Sagimet Biosciences Inc. (SGMT) Merck & Co., Inc. (MRK) Adlai Nortye Ltd (ANL) Corcept Therapeutics Inc. (CORT) Pharming Group N.V. (PHAR) Align Technology, Inc. (ALGN) Novo-Nordisk (NVO) Evommune, Inc. (EVMN) SuperRare (RARE) Cognition Therapeutics, Inc. (CGTX) AstraZeneca PLC (AZN) Synthetify (SNY) Novartis AG (NVS) bioAffinity Technologies, Inc. (BIAF) Array Technologies, Inc. (ARRY) Alkermes Inc. plc (ALKS) Seagen Inc (SGEN) Immunogen Inc (IMGN) Upstream Bio, Inc. (UPB) CalciMedica, Inc. (CALC) GH Research PLC (GHRS) AltLayer (ALT)
Top Social Posts
Top posts by engagements in the last [--] hours
"$UPB reported Phase [--] VALIANT trial results for verekitug in severe asthma showing statistically significant reductions in exacerbation rates (up to 56%) and meaningful improvements in lung function and FeNO across key dosing regimens. $UPB $QNCX $STIM $ELAB $BFRI $MRNA $HURA $PHIO $AIM $DBVT See More Pre-market Movers https://www.biopharmcatalyst.com/news/2026/upstream-bio-upb-phase-2-data-quince-qncx-strategic-alternatives https://www.biopharmcatalyst.com/news/2026/upstream-bio-upb-phase-2-data-quince-qncx-strategic-alternatives"
X Link 2026-02-11T13:40Z 30.7K followers, [----] engagements
"$EVAX will present new biomarker and immune data for its personalized cancer vaccine EVX-01 in advanced melanoma at SITC [----] complementing upcoming two-year efficacy results from its Phase [--] KEYTRUDA combination trial being presented at ESMO [----]. $PALI $ANRO $OVID $IMAB $BOLT $EVAX $APLIF $CLNN $SPRC $OCEA See More Biotech Updates👇 https://www.biopharmcatalyst.com/news/2025/alto-neuroscience-anro-fast-track-designation-evaxion-evax-esmo-data https://twitter.com/i/web/status/1974210485022085549"
X Link 2025-10-03T20:30Z 30.7K followers, [----] engagements
"$ALUR reported initial 12-month results from a study combining its Smart Capsule program with low-dose tirzepatide showing 23% average total weight loss and a 14% increase in lean body mass with full patient adherence and no early discontinuations $ALUR $CTNM $ESPR $CMND $KTTA $TPST $KZIA $PMBC $CLSD $ADTX See More Biotech Updates👇 https://www.biopharmcatalyst.com/news/2025/quantum-biopharma-qntm-30-lawsuit-allurion-technologies-alur-31-data https://twitter.com/i/web/status/1993432139363197340"
X Link 2025-11-25T21:30Z 30.7K followers, [----] engagements
"$HURA entered a definitive agreement to raise https://www.biopharmcatalyst.com/news/2025/wave-life-wve-phase-1-data-structure-therapeutics-gpcr-phase-2-weight-loss-data https://www.biopharmcatalyst.com/news/2025/wave-life-wve-phase-1-data-structure-therapeutics-gpcr-phase-2-weight-loss-data"
X Link 2025-12-09T21:30Z 30.7K followers, [----] engagements
"$CYTK announced that the FDA has approved MYQORZO (aficamten) [--] mg [--] mg [--] mg [--] mg tablets for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and symptoms. $FOLD $GALT $MGRX $CYTK $SAVA $GANX $CALC $BYSI $GOVX $PBM See More Biotech Updates👇 https://www.biopharmcatalyst.com/news/2025/amicus-fold-acquired-by-biomarin-galectin-galt-fda-feedback https://www.biopharmcatalyst.com/news/2025/amicus-fold-acquired-by-biomarin-galectin-galt-fda-feedback"
X Link 2025-12-19T21:34Z 30.7K followers, [----] engagements
"$GHRS announced that the FDA has lifted the clinical hold on its Investigational New Drug Application (IND) for GH001. Phase [--] is planned for [----]. $GHRS $RDHL $ALT $ZBIO $SLRX $NMRA $CNTX $TENX $PLRZ $GOVX See More Pre-market Movers https://www.biopharmcatalyst.com/news/2026/gh-research-ghrs-hold-lifted-altimmune-alt-breakthrough-therapy-designation https://www.biopharmcatalyst.com/news/2026/gh-research-ghrs-hold-lifted-altimmune-alt-breakthrough-therapy-designation"
X Link 2026-01-05T13:40Z 30.7K followers, [----] engagements
"$TIL announced that its subsidiary Axion Bio has discontinued development of AXN-2510 and terminated its license agreement with ImmuneOnco returning all rights to ImmuneOnco while retaining a limited license solely to wind down clinical activities. $TIL $ALMS $CYCN $DRUG $RNAZ $KALA $WVE $ARWR $RDHL $INM See More Pre-market Movers https://www.biopharmcatalyst.com/news/2026/instil-til-terminated-license-agreement-alumis-alms-phase-3-data http://1541.HK http://1541.HK https://www.biopharmcatalyst.com/news/2026/instil-til-terminated-license-agreement-alumis-alms-phase-3-data http://1541.HK"
X Link 2026-01-06T13:40Z 30.7K followers, [----] engagements
"$CGON announced that topline Phase [--] data from the PIVOT-006 trial evaluating cretostimogene as adjuvant monotherapy in intermediate-risk NMIBC is now expected in 1H [----] nearly a year ahead of schedule due to rapid enrollment. As the first randomized registrational trial in this underserved patient group the study's accelerated timeline highlights strong clinical interest and significant unmet need potentially positioning cretostimogene as the first FDA-approved option for this indication. $AQST $CGON $QURE $IBIO $KALV $LQDA $ZVSA $ELVN $GRI $WINT See More Biotech Updates👇"
X Link 2026-01-09T21:30Z 30.7K followers, [----] engagements
"$LYRA has suspended development of LYR-210 for chronic rhinosinusitis and is implementing a full workforce reduction retaining only key executives as consultants while pursuing strategic alternatives with SSG Capital Advisors. The move effectively ends active operations as the company shifts focus to preserving capital and exploring options for its lead asset. $LYRA $DAWN $ABVX $BDSX $TEM $ADPT $JAGX $IRIX $MESO $WOK See More Pre-market Movers https://www.biopharmcatalyst.com/news/2026/lyra-therapeutics-lyra-suspended-lyr-210-development-day-one-dawn-revenue-update"
X Link 2026-01-12T13:40Z 30.7K followers, [----] engagements
"$ATRA received an FDA Complete Response Letter for EBVALLO reversing prior alignment by now deeming the single-arm ALLELE trial insufficient to support accelerated approval for EBV+ PTLD. $ATRA $LYRA $BIOA $DAWN $BDSX $FHTX $CLRB $FBRX $WINT $SHPH See More Biotech Updates👇 https://www.biopharmcatalyst.com/news/2026/atara-atra-57-crl-lyra-lyra-45-lyr-210-suspended https://www.biopharmcatalyst.com/news/2026/atara-atra-57-crl-lyra-lyra-45-lyr-210-suspended"
X Link 2026-01-12T21:30Z 30.7K followers, [----] engagements
"$XTLB is acquiring 85% of NeuroNOS from $XAIR gaining a platform for autism biology and two FDA orphan drug designations (PMS and glioblastoma). With leadership including Nobel Laureates and Prof. Haitham Amal XTL enters the high-need autism market which affects [--] in [--] U.S. children and lacks disease-modifying therapies. $DCOY $XTLB $BCTX $TRAW $TVTX $SPRC $IMRN $ERAS $SXTC $RGC See More Biotech Updates👇 https://www.biopharmcatalyst.com/news/2026/xtl-biopharmaceuticals-xtlb-50-xair-deal-decoy-dcoy-41-partnership"
X Link 2026-01-13T21:30Z 30.7K followers, [----] engagements
"BioPharmCatalyst Weekly #Watchlist BioPharmCatalyst Weekly Watchlist: Key PDUFA and Regulatory Catalysts for the next [--] months $AXSM $RGNX $REPL $RCKT $RYTM $ARVN $TVTX $MNKD $DNLI $ACHV https://www.biopharmcatalyst.com/news/2026/biopharmcatalyst-weekly-watchlist-key-pdufa-and-regulatory-catalysts-for-the-next-6-months-2 https://www.biopharmcatalyst.com/news/2026/biopharmcatalyst-weekly-watchlist-key-pdufa-and-regulatory-catalysts-for-the-next-6-months-2"
X Link 2026-01-16T21:28Z 30.7K followers, [----] engagements
"$LSTA announced it has signed a binding term sheet for a potential acquisition by private biotech firm Kuva Labs for up to $53 million. Kuva will pay $4.00 per share in cash representing an 85% premium to Lisatas prior closing price $LSTA $PBM $ZURA $IOBT $NVAX $VERO $ADTX $CUE $AKAN $LEGN See More Biotech Updates👇 https://www.biopharmcatalyst.com/news/2026/psyence-pbm-reverse-stock-split-postponed-lisata-therapeutics-acquired-by-kuva-labs https://www.biopharmcatalyst.com/news/2026/psyence-pbm-reverse-stock-split-postponed-lisata-therapeutics-acquired-by-kuva-labs"
X Link 2026-01-21T21:30Z 30.7K followers, [----] engagements
"BioPharmCatalyst Weekly #Watchlist BioPharmCatalyst Weekly Watchlist: Key mid-2026 and Other Near-term Catalysts $NTLA $RLYB $MNOV $SDGR $OCS $BMEA $SGMT $AVBP $AVIR $CTNM https://www.biopharmcatalyst.com/news/2026/biopharmcatalyst-weekly-watchlist-key-mid-2026-and-other-near-term-catalysts https://www.biopharmcatalyst.com/news/2026/biopharmcatalyst-weekly-watchlist-key-mid-2026-and-other-near-term-catalysts"
X Link 2026-01-23T21:20Z 30.7K followers, [----] engagements
"$MRK has ended acquisition talks with $RVMD after failing to agree on a valuation with discussions reportedly valuing the biotech at around $30 billion. $SXTP $RVMD $REVB $SRPT $IOBT $COGT $ABOS $INMD $TBPH $MESO See More Pre-market Movers https://www.biopharmcatalyst.com/news/2026/revolution-medicines-rvmd-acquistion-talks-with-mrk-end-60-degrees-pharmaceuticals-sxtp-delisting https://www.biopharmcatalyst.com/news/2026/revolution-medicines-rvmd-acquistion-talks-with-mrk-end-60-degrees-pharmaceuticals-sxtp-delisting"
X Link 2026-01-26T13:40Z 30.7K followers, [----] engagements
"$CALC discontinued its Phase [--] KOURAGE trial of Auxora in AKI with AHRF after an IDMC-recommended safety review flagged concerns warranting study design reevaluation despite no drug-related deaths or serious adverse events. The company will analyze unblinded data to guide potential future development in AKI while continuing plans for a pivotal trial in acute pancreatitis and advancing its second CRAC channel inhibitor. $CALC $ALT $RADX $PHGE $JUNS $STEX $FEED $KRRO $HIND $NUWE See More Pre-market Movers"
X Link 2026-01-28T13:40Z 30.7K followers, [----] engagements
"BioPharmCatalyst Weekly Watchlist: Key mid-2026 and Other Near-Term Catalysts $NTLA $RLYB $MNOV $SDGR $OCS $BMEA $SGMT $AVBP $AVIR $CTNM https://www.biopharmcatalyst.com/news/2026/biopharmcatalyst-weekly-watchlist-key-mid-2026-and-other-near-term-catalysts https://www.biopharmcatalyst.com/news/2026/biopharmcatalyst-weekly-watchlist-key-mid-2026-and-other-near-term-catalysts"
X Link 2026-01-29T16:29Z 30.7K followers, [----] engagements
"$ANL was initiated with a Buy rating and $11 price target by Lucid Capital citing its pan-RAS inhibitor AN9025 as a key potential value driver as the asset becomes de-risked $VIVS $ANL $CORT $APRE $PMN $LXRX $ANEB $APM $QNCX $DRMA See More Biotech Updates👇 https://www.biopharmcatalyst.com/news/2026/vivosim-labs-vivs-commercial-access-china-sxt-pharmaceuticals-sxtc-reverse-split https://www.biopharmcatalyst.com/news/2026/vivosim-labs-vivs-commercial-access-china-sxt-pharmaceuticals-sxtc-reverse-split"
X Link 2026-01-30T22:05Z 30.7K followers, [----] engagements
"BioPharmCatalyst Weekly #Watchlist BioPharmCatalyst Weekly Watchlist: Key Catalysts Over The Next Two months $GOSS $RGNX $PVLA $KOD $ALDX $ACET $TBPH $FGEN $KPTI $ALZN https://www.biopharmcatalyst.com/news/2026/biopharmcatalyst-weekly-watchlist-key-catalysts-over-the-next-two-months https://www.biopharmcatalyst.com/news/2026/biopharmcatalyst-weekly-watchlist-key-catalysts-over-the-next-two-months"
X Link 2026-01-31T16:00Z 30.7K followers, [----] engagements
"$ELAB completed its third CNC shop acquisition buying SVM Machining for $2.25M plus earnouts expanding its precision manufacturing platform across aerospace medical and semiconductor sectors. $ELAB $EVO $ANL $CRBU $PHAR $APM $CDT $ATOS $HURA $VIVS See More Pre-market Movers https://www.biopharmcatalyst.com/news/2026/pmgc-holdings-elab-acquisition-evotec-evo-analyst-rating https://www.biopharmcatalyst.com/news/2026/pmgc-holdings-elab-acquisition-evotec-evo-analyst-rating"
X Link 2026-02-03T13:40Z 30.7K followers, [----] engagements
"$SGMO priced a $25M+ offering amid strong Phase 1/2 STAAR data showing ST-920 improved kidney and cardiac function in Fabry disease supporting a rolling BLA submission to FDA. $SGMO $ELAB $RLYB $ERNA $EVO $RLAY $CDT $EPRX $SXTC $QNCX See More Biotech Updates👇 https://www.biopharmcatalyst.com/news/2026/sangamo-therapeutics-sgmo-31-private-placement-pmgc-holdings-elab-40-acquisition https://www.biopharmcatalyst.com/news/2026/sangamo-therapeutics-sgmo-31-private-placement-pmgc-holdings-elab-40-acquisition"
X Link 2026-02-03T21:40Z 30.7K followers, [----] engagements
"$NVST reported strong Q4 [----] results with core sales growth of 10.8% and a 22% increase in adjusted EBITDA to $111 million. Adjusted EPS rose 58% year-over-year to $0.38. For full-year [----] core sales grew 6.5% and adjusted EBITDA increased 26% reaching $372 million. CEO Paul Keel highlighted solid growth across all major businesses and geographies improved employee engagement and $166 million returned to shareholders via stock buybacks. Envista guided for [----] adjusted EPS of $1.35$1.45 core sales growth of 24% and free cash conversion of"
X Link 2026-02-06T13:40Z 30.7K followers, [----] engagements
"$VTYX surged after hours on reports that $LLY is in advanced talks to acquire the company with a deal potentially imminent. Ventyx focused on oral therapies for inflammatory diseases currently has a $600M market cap. $VTYX $ALMS $CYCN $TIL $ACRV $DRUG $RGC $BIOA $MREO $BNR See More Biotech Updates👇 https://www.biopharmcatalyst.com/news/2026/alumis-alms-phase-3-data-cyclerion-cycn-collaboration https://www.biopharmcatalyst.com/news/2026/alumis-alms-phase-3-data-cyclerion-cycn-collaboration"
X Link 2026-01-06T21:30Z 30.7K followers, [----] engagements
"$IMRX announced encouraging updated Phase 2a data for Atebimetinib in combination with modified gemcitabine/nab-paclitaxel in first-line metastatic pancreatic cancer showing a 64% 12-month overall survival rate vs. https://www.biopharmcatalyst.com/news/2026/immuneering-imrx-phase-2a-data-eli-lilly-lly-will-acquire-ventyx-biosciences-vtyx https://www.biopharmcatalyst.com/news/2026/immuneering-imrx-phase-2a-data-eli-lilly-lly-will-acquire-ventyx-biosciences-vtyx"
X Link 2026-01-08T13:40Z 30.7K followers, [----] engagements
"$AQST announced receipt of a CRL from the FDA for its sublingual film epinephrine treatment Anaphylm citing human factors deficiencies related to packaging and administration including difficulty opening the pouch and incorrect film placement. $AQST $THAR $SER $PHAR $MOLN $HIND $SXTC $VERO $APRE $NUWE See More Pre-market Movers https://www.biopharmcatalyst.com/news/2026/aquestive-therapeutics-aqst-crl-pharming-group-phar-crl https://www.biopharmcatalyst.com/news/2026/aquestive-therapeutics-aqst-crl-pharming-group-phar-crl"
X Link 2026-02-02T13:40Z 30.7K followers, [----] engagements
"$ALGN topped Wall Street estimates for both earnings and revenue. Driven by strong demand for its Invisalign system Align reported Q4 adjusted earnings of $3.29 per share on revenue of $1.05 billionabove analyst expectations of $2.97 per share and $1.03 billion. Clear Aligner revenue grew 5.5% to $838 million. For Q1 Align guided revenue between $1.01 billion and $1.03 billion and projected a 19.5% operating margin slightly below consensus. While Needhams David Saxon maintained a Hold rating he noted the outlook was fairly achievable amid strong U.S. and international sales. $ALGN $ALXO $TPST"
X Link 2026-02-05T13:40Z 30.7K followers, [----] engagements
"$ALGN topped Wall Street estimates for both earnings and revenue. Driven by strong demand for its Invisalign system Align reported Q4 adjusted earnings of $3.29 per share on revenue of $1.05 billionabove analyst expectations of $2.97 per share and $1.03 billion. Clear Aligner revenue grew 5.5% to $838 million. For Q1 Align guided revenue between $1.01 billion and $1.03 billion and projected a 19.5% operating margin slightly below consensus. While Needhams David Saxon maintained a Hold rating he noted the outlook was fairly achievable amid strong U.S. and international sales. $ALGN $ALXO $TPST"
X Link 2026-02-05T15:06Z 30.7K followers, [----] engagements
"$RGNX announced the FDA has issued a Complete Response Letter (CRL) for its BLA submission of RGX-121 for MPS II (Hunter syndrome) citing concerns over patient eligibility criteria use of external controls and surrogate endpoints. $RGNX $TNON $HUMA $LNAI $BCAB $QNCX $ENSC $HURA $ERNA $LYRA See More Biotech Updates👇 https://www.biopharmcatalyst.com/news/2026/regenxbio-rgnx-halt-complete-response-letter-crl-humacyte-huma-30-dod-funding https://www.biopharmcatalyst.com/news/2026/regenxbio-rgnx-halt-complete-response-letter-crl-humacyte-huma-30-dod-funding"
X Link 2026-02-09T21:39Z 30.7K followers, [----] engagements
"$PHAR announced that the FDA issued a Complete Response Letter for the sNDA to expand Joenja (leniolisib) for APDS patients aged [---] citing concerns about potential underexposure in lower-weight children and an analytical testing method. $AQST $CATX $PHAR $SER $HIND $SGMT $SXTC $APLM $BCAB $ATOS See More Biotech Updates👇 https://www.biopharmcatalyst.com/news/2026/aquestive-therapeutics-crl-perspective-therapeutics-catx-offering https://www.biopharmcatalyst.com/news/2026/aquestive-therapeutics-crl-perspective-therapeutics-catx-offering"
X Link 2026-02-02T21:34Z 30.7K followers, [----] engagements
"$IRON received a CRL from the FDA for bitopertin in erythropoietic protoporphyria (EPP) with the agency acknowledging that the Phase [--] AURORA and BEACON trials showed significant reductions in whole blood metal-free PPIX and strong mechanistic support for the biomarker but concluding the data did not demonstrate a clear association between PPIX reductions and sunlight exposure-based clinical endpoints. The FDA indicated that results from the ongoing Phase [--] APOLLO trial could support traditional approval with topline data expected in Q4 [----]. The company plans to request a Type A meeting with"
X Link 2026-02-13T20:24Z 30.7K followers, [----] engagements
"$PHRRF announced that the FDA has approved the Company's ketamine product herein referred to as KETARx on August 8th [----] for its indicated uses in surgical pain management. https://www.biopharmcatalyst.com/company/PHRRF/news/287382 https://www.biopharmcatalyst.com/company/PHRRF/news/287382"
X Link 2025-08-11T13:30Z 30.7K followers, [----] engagements
"$CLSD filed for Chapter [--] bankruptcy and will pursue a sale of its assets under Section [---] aiming to maximize stakeholder value via its SCS Microinjector platform five licensing deals with royalty potential and clinical-stage programs including Phase 3-ready CLS-AX for wet AMD and IND-ready assets in geographic atrophy and DME. $CLSD $ENLV $PMN $INSP $NVO $GNTA $ADTX $NAOV $SHPH $OABI See More Pre-market Movers https://www.biopharmcatalyst.com/news/2025/clearside-biomedical-clsd-chapter-11-enlivex-therapeutics-enlv-phase-2a-data-pipe"
X Link 2025-11-24T13:40Z 30.7K followers, [----] engagements
"$MOVE reported that its merger partner Corvex secured a long-term lease for Nvidia H200 GPUs. The companies announced an all-stock merger in November with Corvex shareholders to own https://www.biopharmcatalyst.com/news/2026/greenwich-lifesciences-glsi-manufacturing-update-gri-bio-gri-reverse-stock-split https://www.biopharmcatalyst.com/news/2026/greenwich-lifesciences-glsi-manufacturing-update-gri-bio-gri-reverse-stock-split"
X Link 2026-01-23T13:40Z 30.7K followers, [----] engagements
"$ADAG ended [----] with $74.5M in cash funding operations into late [----]. A Q1 [----] data update is expected from the Phase 1b/2 study of muzastotug + pembrolizumab in 3L+ MSS colorectal cancer. In [----] muzastotug received FDA Fast Track designation and showed promising early efficacy/safety. $MOVE $ADAG $REVB $PRFX $CHRS $BHC $ANL $SCNI $IOBT $BNR See More Biotech Updates👇 https://www.biopharmcatalyst.com/news/2026/adagene-adag-23-update-movano-move-140-nvidia-deal https://www.biopharmcatalyst.com/news/2026/adagene-adag-23-update-movano-move-140-nvidia-deal"
X Link 2026-01-23T21:34Z 30.7K followers, [----] engagements
"$ALGN topped Wall Street estimates for both earnings and revenue. Driven by strong demand for its Invisalign system Align reported Q4 adjusted earnings of $3.29 per share on revenue of $1.05 billionabove analyst expectations of $2.97 per share and $1.03 billion. Clear Aligner revenue grew 5.5% to $838 million. For Q1 Align guided revenue between $1.01 billion and $1.03 billion and projected a 19.5% operating margin slightly below consensus. While Needhams David Saxon maintained a Hold rating he noted the outlook was fairly achievable amid strong U.S. and international sales. $ALGN $ALXO $TPST"
X Link 2026-02-05T15:04Z 30.7K followers, [----] engagements
"BioPharmCatalyst Weekly #Watchlist BioPharmCatalyst Weekly Watchlist: Anticipated Key Catalysts Due Over Next [--] Months $AXSM $DNLI $MIRM $NBTX $RYTM $ADCT $VRDN $OCS $AVIRI $CTMN https://www.biopharmcatalyst.com/news/2026/biopharmcatalyst-weekly-watchlist-anticipated-key-catalysts-due-over-next-6-months-2 https://www.biopharmcatalyst.com/news/2026/biopharmcatalyst-weekly-watchlist-anticipated-key-catalysts-due-over-next-6-months-2"
X Link 2026-02-06T21:45Z 30.7K followers, [----] engagements
"$ERNA priced a $10.5M best-efforts public offering of 21M shares (or equivalents) and accompanying warrants at $0.50 per unit with warrants exercisable at $0.68 and expiring either five years post-issuance or [---] days after initial ERNA-101 Phase [--] cohort data release. Proceeds will fund development programs and operations with potential for $14.3M in additional gross proceeds if warrants are fully exercised. $ERNA $PLSE $ANEB $NVST $ATPC $ROIV $HURA $DNA $ESLA $ENVB See More Biotech Updates👇"
X Link 2026-02-06T21:46Z 30.7K followers, [----] engagements
"$TNON reaffirmed its strong [----] revenue outlook projecting Q4 revenue of $1.45M$1.48M (up https://www.biopharmcatalyst.com/news/2026/tenon-medical-tnon-earnings-guidance-artelo-biosciences-artl-equity-purchase-agreement https://www.biopharmcatalyst.com/news/2026/tenon-medical-tnon-earnings-guidance-artelo-biosciences-artl-equity-purchase-agreement"
X Link 2026-02-09T13:40Z 30.7K followers, [----] engagements
"$EVMN reported Phase 2a results for EVO301 in moderate-to-severe atopic dermatitis meeting the primary efficacy endpoint with a 33% placebo-adjusted EASI improvement at week [--] and 23% of patients achieving IGA 0/1. The IL-18 inhibitor showed rapid statistically significant efficacy at weeks [--] [--] and [--] with a clean safety profile supporting advancement to a Phase 2b dose-ranging trial and broader development plans. $ABP $QNCX $PSNL $NKTR $PHIO $MIRA $PHG $HURA $TECX $ENSC See More Pre-market Movers"
X Link 2026-02-10T13:40Z 30.7K followers, [----] engagements
"$QNCX announced that it is hiring LifeSci Capital to explore strategic alternatives including partnerships M&A licensing or balance-sheet restructuring though no outcome or timeline has been disclosed. $QNCX $EVMN $NKTR $PHIO $BRTX $PHGE $HURA $LNAI $ENSC $TECX See More Biotech Updates👇 https://www.biopharmcatalyst.com/news/2026/quince-qncx-306-strategic-alternatives-nektar-nktr-51-phase-2b-data https://www.biopharmcatalyst.com/news/2026/quince-qncx-306-strategic-alternatives-nektar-nktr-51-phase-2b-data"
X Link 2026-02-10T21:31Z 30.7K followers, [----] engagements
"$NVCR shares are up following FDA approval of Optune Pax for locally advanced pancreatic cancer marking the first new treatment in decades. The wearable device used with gemcitabine and nab-paclitaxel improved overall survival in a Phase [--] trial. $NVCR $QNCX $VKTX $MCRB $BRTX $BBIO $CTNM $PLRZ $ICLR $ABP See More Pre-market Movers https://www.biopharmcatalyst.com/news/2026/novocure-nvcr-approval-bridgebio-bbio-phase-3-dat https://www.biopharmcatalyst.com/news/2026/novocure-nvcr-approval-bridgebio-bbio-phase-3-dat"
X Link 2026-02-12T13:40Z 30.7K followers, [----] engagements
"$IMUX issued warrants to purchase up to [---------] shares (or pre-funded warrants) at $0.873/share potentially raising an additional $200 million. The warrants expire [--] days post-Phase [--] ENSURE top-line data announcement or February [--] [----]. This private placement expected to close around February [--] [----] supports Immunic's transition to the commercial stage. $IMUX $VTGN $CHRS $QNCX $BIO $OKYO $JSPR $BRTX $ABP $ARTL See More Pre-market Movers https://www.biopharmcatalyst.com/news/2026/immunic-imux-warrants-coherus-oncology-chrs-offering"
X Link 2026-02-13T13:40Z 30.7K followers, [----] engagements
"BioPharmCatalyst Weekly #Watchlist BioPharmCatalyst Weekly Watchlist: Key Phase [--] catalysts left for the quarter $OCUL $BCRX $GOSS $BCDA $KOD $TBPH $KPTI $PVLA https://www.biopharmcatalyst.com/news/2026/biopharmcatalyst-weekly-watchlist-key-phase-3-catalysts-left-for-the-quarter https://www.biopharmcatalyst.com/news/2026/biopharmcatalyst-weekly-watchlist-key-phase-3-catalysts-left-for-the-quarter"
X Link 2026-02-13T21:33Z 30.7K followers, [----] engagements
"$ONCY reported significant coordinated insider buying across all executive and board levels on February [----] [----]. Purchases between $0.83 and $0.86 per share signal strong confidence at the current price; shares closed up 26%. $IRON $ONCY $PHIO $CHRS $OKYO $EVMN $AIM $ICLR $INTS $UPB See More Biotech Updates👇 https://www.biopharmcatalyst.com/news/2026/disc-iron-22-complete-response-letter-crl-oncolytics-oncy-27-insider-buys https://www.biopharmcatalyst.com/news/2026/disc-iron-22-complete-response-letter-crl-oncolytics-oncy-27-insider-buys"
X Link 2026-02-13T21:35Z 30.7K followers, [---] engagements
"Want more info analysis and biotech news straight to your inbox Sign up for our FREE Daily and Weekly newsletters here: https://bit.ly/BPCNewsletters https://bit.ly/BPCNewsletters"
X Link 2025-07-14T19:02Z 29.7K followers, [----] engagements
"$SRPT announced a strategic restructuring to prioritize high-impact programs ensure financial sustainability through [----] and focus on siRNA platform opportunities. The plan includes $400M in annual cost savings and a 36% workforce reduction (500 employees) aiming for long-term growth and profitability. See More Biotech Updates👇 $APM $CUE $CYCC $NUWE $QLGN $RPTX $GANX $CGTX $IKNA https://www.biopharmcatalyst.com/news/2025/aptorum-group-apm-100-all-stock-merger-nuwellis-nuwe-131-patent https://www.biopharmcatalyst.com/news/2025/aptorum-group-apm-100-all-stock-merger-nuwellis-nuwe-131-patent"
X Link 2025-07-16T20:29Z 29.9K followers, [----] engagements
"Want more info analysis and biotech news straight to your inbox Sign up for our FREE Daily and Weekly newsletters here: https://bit.ly/BPCNewsletters https://bit.ly/BPCNewsletters"
X Link 2025-07-16T21:44Z 29.9K followers, [----] engagements
"$WINT signed a $60M securities purchase agreement led by Build and Build Corp with the potential to raise a total of $200M to launch a BNB crypto treasury strategy. Subject to shareholder approval Windtree aims to become the first NASDAQ-listed company offering direct BNB token exposure. See More Pre-market Movers 👇 $WINT $SRPT $PRTC $RCKT $NUWE https://www.biopharmcatalyst.com/news/2025/windtree-wint-securities-purchase-agreement-sarepta-srpt-restructuring https://www.biopharmcatalyst.com/news/2025/windtree-wint-securities-purchase-agreement-sarepta-srpt-restructuring"
X Link 2025-07-17T12:23Z 29.9K followers, [----] engagements
"$CLSD initiated a strategic review to explore options including asset sales partnerships or M&A to advance its SCS platform; Piper Sandler retained to lead the process. See More Biotech Updates👇 $WINT $SRPT $RCKT $FOLD $MBRX $CLSD $ICU https://www.biopharmcatalyst.com/news/2025/windtree-wint-17-securities-purchase-agreement-clearside-clsd-28-strategic-review https://www.biopharmcatalyst.com/news/2025/windtree-wint-17-securities-purchase-agreement-clearside-clsd-28-strategic-review"
X Link 2025-07-17T20:25Z 30.1K followers, [----] engagements
"$TELO reported promising data for Telomir-1 which showed it could reverse epigenetic gene silencing and restore tumor suppressors in human prostate cancer cells outperforming chemotherapy and rapamycin. See More Pre-market Movers 👇 $MESO $CNSP $SRPT $WINT $IINN https://www.biopharmcatalyst.com/news/2025/telomir-telo-telomir-1-data-mesoblast-meso-revenue https://www.biopharmcatalyst.com/news/2025/telomir-telo-telomir-1-data-mesoblast-meso-revenue https://www.biopharmcatalyst.com/news/2025/telomir-telo-telomir-1-data-mesoblast-meso-revenue"
X Link 2025-07-18T12:20Z 30.2K followers, [----] engagements
"BioPharmCatalyst Weekly #Watchlist Key Catalysts Due in Mid-2025 $REPL $OTLK $RARE $WINT $ATAI $CYBN $IXHL $TNXP $VYNE $ATHE $PFE $CRDF $PRAX https://www.biopharmcatalyst.com/news/2025/key-catalysts-due-in-mid-2025 https://www.biopharmcatalyst.com/news/2025/key-catalysts-due-in-mid-2025"
X Link 2025-07-19T15:00Z 30.1K followers, [----] engagements
"$ITOS to be acquired by Concentra Biosciences for $10.047/share in cash plus a CVR tied to net cash above $475M and potential asset sales; tender offer to begin by Aug [--] [----]. See More Pre-market Movers 👇 $PMN $HSDT $ZIMV $SABS $NCNA $AUTL $EVO https://www.biopharmcatalyst.com/news/2025/promis-pmn-fast-track-designation-helius-hsdt-data https://www.biopharmcatalyst.com/news/2025/promis-pmn-fast-track-designation-helius-hsdt-data"
X Link 2025-07-21T12:20Z 30.1K followers, [----] engagements
"$PMN shares closed up after the company announced that PMN310 its lead therapeutic candidate for Alzheimer's received FDA Fast Track designation. See More Biotech Updates👇 $PMN $ZIMV $EVO $SABS $HOOK $SLRX $CLSD $GDTC https://www.biopharmcatalyst.com/news/2025/zimvie-zimv-122-acquired-by-archimed-promis-pmn-154-fast-track-designation https://www.biopharmcatalyst.com/news/2025/zimvie-zimv-122-acquired-by-archimed-promis-pmn-154-fast-track-designation"
X Link 2025-07-21T20:58Z 30K followers, [----] engagements
"$REPL received a Complete Response Letter from the FDA for its BLA for RP1 with nivolumab in advanced melanoma citing the IGNYTE trial as inadequate due to patient heterogeneity and confirmatory trial design issues; no safety concerns were noted. Replimune plans to request a Type A meeting to discuss accelerated approval. See More Pre-market Movers 👇 $PMN $QNTM $STRO $GNLX $SPRC https://www.biopharmcatalyst.com/news/2025/replimune-repl-crl-promis-pmn-offering https://www.biopharmcatalyst.com/news/2025/replimune-repl-crl-promis-pmn-offering"
X Link 2025-07-22T12:24Z 29.9K followers, [----] engagements
"$ABVX shares are halted following results that its 50mg obefazimod achieved 16.4% pooled placebo-adjusted clinical remission at [--] weeks in Phase [--] ABTECT induction trials for moderate-to-severe UC meeting all key secondary endpoints with favorable safety. Maintenance data is due 2Q [----] ahead of planned NDA/MAA submissions in 2H [----]. The company also delayed 1H [----] financial results from August [--] to September [--] [----]. Preliminary cash and cash equivalents as of June [--] [----] were approximately $71.4 million (unaudited). See More Biotech Updates👇 $IOVA $REPL $PMN $QNTM $STRO $AMIX $ABVX"
X Link 2025-07-22T20:51Z 29.9K followers, [----] engagements
"$ANEB announced a proposed reverse stock split at a ratio between 1-for-2500 and 1-for-7500 as part of a plan to go private by reducing its number of shareholders. Stockholders with fewer than the minimum required shares post-split will be cashed out at $3.50 per pre-split share a 91% premium over the July [--] [----] closing price. The split is subject to stockholder approval and other conditions. See More Pre-market Movers 👇 $CLSD $IMNN $PHVS $IOVA $LTRN https://www.biopharmcatalyst.com/news/2025/anebulo-aneb-reverse-stock-split-clearside-biomedical-clsd-canada-approval"
X Link 2025-07-23T12:22Z 29.9K followers, [----] engagements
"$CLSD announced that Health Canada has granted approval for XIPERE for suprachoroidal use in the treatment of uveitic macular edema (UME). See More Biotech Updates👇 $ABVX $ANEB $CLSD $IMNN $GHRS $PHVS $IOVA $LTRN https://www.biopharmcatalyst.com/news/2025/abivax-abvx-586-phase-3-data-anebulo-aneb-82-reverse-splite https://www.biopharmcatalyst.com/news/2025/abivax-abvx-586-phase-3-data-anebulo-aneb-82-reverse-splite"
X Link 2025-07-23T20:41Z 30.1K followers, [----] engagements
"$ADAP will sell TECELRA lete-cel afami-cel and uza-cel to US WorldMeds for $55M upfront and up to $30M in milestones. US WorldMeds will handle commercialization and development while Adaptimmune focuses on preclinical programs (PRAME CD70 allogeneic) and will restructure. See More Biotech Updates👇 $CELC $ENTX $ADAP $ATHE $STXS $LYEL https://www.biopharmcatalyst.com/news/2025/celcuity-celc-167-phase-3-data-adaptimmune-adap-71-tecelra-sale https://www.biopharmcatalyst.com/news/2025/celcuity-celc-167-phase-3-data-adaptimmune-adap-71-tecelra-sale"
X Link 2025-07-28T20:43Z 30K followers, [----] engagements
"$CLDI received FDA Fast Track designation for CLD-201 (SuperNova) its allogeneic adipose stem-cell loaded oncolytic virus for the treatment of soft tissue sarcoma. See More Pre-market Movers 👇 $DRRX $SCNI $SLRX $FULC $SRPT $APLS $NVO $ADAP $NEO https://www.biopharmcatalyst.com/news/2025/durect-drrx-acquired-by-bausch-bhc-calidi-cldi-fast-track-designation-ftd https://www.biopharmcatalyst.com/news/2025/durect-drrx-acquired-by-bausch-bhc-calidi-cldi-fast-track-designation-ftd"
X Link 2025-07-29T12:21Z 30K followers, [----] engagements
"$SNGX reported results from an eight-patient Phase 2a study of SGX945 (dusquetide) in Behets-related ulcers showing a 40% efficacy improvement over historical placebo with no drug-related adverse events. Benefits were comparable to apremilast and persisted post-treatment. The company plans to reformulate for subcutaneous dosing and pursue a placebo-controlled Phase [--] trial. See More Pre-market Movers 👇 $ENSC $IHXL $DYAI $APLS $PBM $PRME https://www.biopharmcatalyst.com/news/2025/soligenix-sngx-phase-2a-data-ensysce-ensc-breakthrough-therapy-designation"
X Link 2025-07-31T12:24Z 30K followers, [----] engagements
"$GRI reported 6-week interim biomarker data from its Phase 2a IPF trial of GRI-0621 showing reduced fibrogenesis markers and a net fibrolytic profile in treated patients. The data suggest enhanced ECM remodeling and potential tissue repair. The IDMC recommended the study continue as planned citing no safety concerns and the need for additional data to confirm efficacy versus standard of care. See More Biotech Updates👇 $SNGX $INDV $ALNY $IXHL $GRI $VCEL $APLS $PSTV https://www.biopharmcatalyst.com/news/2025/soligenix-sngx-phase-2a-data-gri-bio-gri-biomarker-dat"
X Link 2025-07-31T20:27Z 30.2K followers, [----] engagements
"$BTAI shares closed up after an H.C. Wainwright analyst reiterated a Buy rating and $8 PT citing the imminent top-line readout from the pivotal SERENITY At-Home Phase [--] safety trial of sub-lingual film BXCL501 (IGALMI) in bipolar and schizophrenia agitation. See More Biotech Updates👇 $CASI $BTAI $REPL $PBM $XOMA $SAVA $SINT $XCUR $MURA $VRTX $INMB https://www.biopharmcatalyst.com/news/2025/casi-pharmaceuticals-casi-investigational-new-drug-ind-bioxcel-btai-analyst https://www.biopharmcatalyst.com/news/2025/casi-pharmaceuticals-casi-investigational-new-drug-ind-bioxcel-btai-analyst"
X Link 2025-08-04T20:35Z 30K followers, [----] engagements
"$GUTS announced a public offering of common stock and warrants following positive 2-year data for its Revita system in obese T2D patients showing 9.6% median weight loss and 1.6% HbA1c reduction with no serious device-related events; results align with prior studies with interim REMAIN-1 data expected in Q3 [----] and primary endpoints in 2H [----] and underwriters granted a 30-day option to purchase an additional 15%. $PHGE $COSM $LNTH $EOLS $GUTS $GERN $CRDL $MNKD $AIMD See More Biotech Updates👇"
X Link 2025-08-06T20:35Z 30.3K followers, [----] engagements
"$EBS exceeded Q2 [----] revenue guidance by $21M and raised the low end/midpoint of full-year profitability outlook citing strong execution of its turnaround plan improved margins and sustained positive cash flow; the company secured seven new biodefense contract modifications and sees continued demand for its naloxone products and medical countermeasures heading into H2. $SANA $LLY $IRWD $XERS $FGEN $EBS $CCCC $AKBA See More Biotech Updates👇 https://www.biopharmcatalyst.com/news/2025/emergent-ebs-earnings-sana-biotechnology-sana-offering"
X Link 2025-08-07T20:30Z 30.2K followers, [----] engagements
"$ENTO announced definitive agreements with institutional investors for the purchase and sale of approximately $3 million in pre-funded and common warrants. The transaction was priced at the market under Nasdaq rules. $IOBT $BJDX $NYXH $AVTR See More Pre-market Movers 👇 https://www.biopharmcatalyst.com/news/2025/entero-therapeutics-ento-warrants-io-biotech-iobt-phase-3-data https://www.biopharmcatalyst.com/news/2025/entero-therapeutics-ento-warrants-io-biotech-iobt-phase-3-data"
X Link 2025-08-11T12:40Z 30.1K followers, [----] engagements
"$ATNF shares rose after a $156 million private offering boosting its Ethereum reserves. This follows a $425 million placement led by over [--] institutional and crypto investors. The firm will rebrand as ETHZilla Corporation reflecting its focus on ETH. $ATNF $CGTX $XFOR $TNXP $ARCT $VERU $DRIO $MYO See More Biotech https://www.biopharmcatalyst.com/news/2025/180-life-sciences-atnf-private-offering-drio-drio-earnings https://www.biopharmcatalyst.com/news/2025/180-life-sciences-atnf-private-offering-drio-drio-earnings"
X Link 2025-08-12T20:38Z 30K followers, [----] engagements
"$CGTX secured FDA alignment on Phase [--] design for zervimesine in mild-to-moderate Alzheimers including p-tau217based patient enrichment six-month treatment duration confirmed endpoints and an open-label extension with two such studies potentially supporting an NDA after Phase [--] data showed 95% slowing of cognitive decline in the enriched population. $ATNF $GBIO $SPRO $SEPN $DERM $CMPX See More Pre-market Movers 👇 https://www.biopharmcatalyst.com/news/2025/180-life-sciences-atnf-crypto-reserves-cognition-therapeutics-cgtx-fda-phase-3-alignment"
X Link 2025-08-13T12:40Z 30.1K followers, [----] engagements
"$SNOA launched its HOCl-based diaper rash hydrogel into major U.S. retail channels now available in [----] Walmart stores on Amazon and in large grocery chains marking its first large-scale U.S. OTC consumer product rollout. $SCLX $LIXT $XFOR $CGTX $GBIO $DERM $SPRO See More Biotech Updates👇 https://www.biopharmcatalyst.com/news/2025/sonoma-pharmaceuticals-snoa-46-product-roll-out-scilex-sclx-19-s-4-filing https://www.biopharmcatalyst.com/news/2025/sonoma-pharmaceuticals-snoa-46-product-roll-out-scilex-sclx-19-s-4-filing"
X Link 2025-08-13T20:30Z 30.1K followers, [----] engagements
"$PGEN announced that the FDA has approved PAPZIMEOS (zopapogene imadenovec-drba) for the treatment of adults with recurrent respiratory papillomatosis (RRP). PAPZIMEOS is the first and only FDA-approved therapy for the treatment of adults with RRP. $HIND $TIVC $IVVD $PSTV $CODX $CSCI See More Pre-market Movers 👇 https://www.biopharmcatalyst.com/news/2025/precigen-pgen-fda-approval-plus-therapeutics-pstv-analyst https://www.biopharmcatalyst.com/news/2025/precigen-pgen-fda-approval-plus-therapeutics-pstv-analyst"
X Link 2025-08-15T12:40Z 30.2K followers, [----] engagements
"$IOBT reported a Q2 loss of $0.40 with cash of $28.1 million at June [--] [----] down from $60 million year-end and secured [----] million from EIB loan tranches in May and July extending runway into Q1 [----]. $PGEN $PSTV $HIND $CSCI $TIVC $IVVD $IOBT $CODX See More Biotech Updates👇 https://www.biopharmcatalyst.com/news/2025/precigen-pgen-59-approval-io-biotech-iobt-69-earnings https://www.biopharmcatalyst.com/news/2025/precigen-pgen-59-approval-io-biotech-iobt-69-earnings"
X Link 2025-08-15T20:30Z 30.1K followers, [----] engagements
"$APM and DiamiR Biosciences received approval from the NYSDOH to offer their APOE Genotyping test which helps assess Alzheimer's disease risk. Aptorum entered into a definitive agreement for an all-stock merger transaction to acquire DiamiR effective July [--] [----] making DiamiR a subsidiary of Aptorum. $IVVD $EVOK $NVAX $IMRX $SRPT $HIND See More Pre-market Movers 👇 https://www.biopharmcatalyst.com/news/2025/aptorum-group-apm-nysdoh-approval-evoke-pharma-evok-patent https://www.biopharmcatalyst.com/news/2025/aptorum-group-apm-nysdoh-approval-evoke-pharma-evok-patent"
X Link 2025-08-21T12:40Z 30.1K followers, [----] engagements
"$PTIX has completed the first dose injections for all subjects in the multiple-dose portion of its Phase [--] clinical trial for PT00114. This novel neuro-active peptide therapy derived from TCAP aims to modulate stress responses for treating various mental health conditions. Dosing is expected to conclude by August with topline safety data by September enabling progression to Phase [--] efficacy studies in Q1 [----]. $APM $PTIX $IVVD $EVOK $SRPT $NVAX $IMRX $HIND $THAR See More Biotech Updates👇"
X Link 2025-08-21T20:30Z 30.3K followers, [----] engagements
"$IXHL authorized a $20M share repurchase program allowing buybacks via open market private transactions or structured arrangements under Rule 10b5-1 and Rule 10b-18. $AZTR $APM $AEMD $EVOK $PTIX See More Pre-market Movers 👇 https://www.biopharmcatalyst.com/news/2025/incannex-ixhl-share-repurchase-program-azitra-aztr-reverse-split https://www.biopharmcatalyst.com/news/2025/incannex-ixhl-share-repurchase-program-azitra-aztr-reverse-split"
X Link 2025-08-22T12:40Z 30.2K followers, [----] engagements
"$IVVD shares are currently up during premarket hours after D. Boral Capital maintained a Buy rating on Invivyd and cut the price target to $1. $AIFF $SER $MRKR $IXHL $PSTV $EPIX $HCWB $VRAX $FEMY See More Pre-market Movers https://www.biopharmcatalyst.com/news/2025/invivyd-ivvd-analyst-firefly-aiff-clear-platform https://www.biopharmcatalyst.com/news/2025/invivyd-ivvd-analyst-firefly-aiff-clear-platform"
X Link 2025-08-26T12:40Z 30.2K followers, [----] engagements
"$CARM will receive a $5M private placement investment from $OCGN as part of its merger with Ocugen subsidiary OrthoCellix with terms ensuring Ocugen receives equal or better investor rights; the deal is contingent on shareholder and regulatory approvals"
X Link 2025-08-29T21:29Z 30.1K followers, [----] engagements
"BioPharmCatalyst Weekly #Watchlist Key Near-term Catalysts $AGIO $FBIO $SRRK $CRNX $INCY $MRK https://www.biopharmcatalyst.com/news/2025/biopharmcatalyst-weekly-watchlist-key-pdufa-dates-left-for-the-quarter https://www.biopharmcatalyst.com/news/2025/biopharmcatalyst-weekly-watchlist-key-pdufa-dates-left-for-the-quarter"
X Link 2025-08-30T15:00Z 30.2K followers, [----] engagements
"$UTHR reported its Phase [--] TETON-2 trial of nebulized Tyvaso in idiopathic pulmonary fibrosis met the primary endpoint with a [----] mL FVC improvement at [--] weeks (p0.0001) with significant benefits across multiple secondary measures and a favorable safety profile. $CARM $MLYS $IONS $HOTH $CYTK $IVA $ARWR See More Pre-market Movers https://www.biopharmcatalyst.com/news/2025/carisma-therapeutics-carm-private-placement-from-ocgn-united-therapeutics-uthr-phase-3-data"
X Link 2025-09-02T12:40Z 30.2K followers, [----] engagements
"$MLYS surged about 86% after AstraZeneca announced positive Phase [--] results for baxdrostat a blood pressure drug similar to Mineralys' lorundrostat. $CARM $WINT $TECX $UTHR $TNFA $MLYS $IONS $HOTH $CYTK $ $IVA $BRKR See More Biotech Updates👇 https://www.biopharmcatalyst.com/news/2025/carisma-carm-private-placement-mineralys-mlys-off-astrazeneca-azn-phase-3-data https://www.biopharmcatalyst.com/news/2025/carisma-carm-private-placement-mineralys-mlys-off-astrazeneca-azn-phase-3-data"
X Link 2025-09-02T20:30Z 30.1K followers, [----] engagements
"$INDP reported completion of the monotherapy arm in its INDP-D101 trial and initiation of seven patients in combination with tislelizumab noting one monotherapy patient previously treated with anti-PD-1 showed a partial response with liver metastasis shrinkage before progressing after four months. $ARTL $AEMD $PPBT $AGIO $SNY $NLSP $VANI $LGVN See More Biotech Updates👇 https://www.biopharmcatalyst.com/news/2025/artelo-biosciences-artl-public-offering-purple-biotech-ppbt-preclinical-data"
X Link 2025-09-04T20:30Z 30.2K followers, [----] engagements
"$AIFF announced a partnership with HealingMaps and Advanced Behavioral Strategies to integrate its FDA-cleared AI-driven EEG brain health platform. $BNTX $THAR $PMN $VANI $QURE $CERO See More Pre-market Movers https://www.biopharmcatalyst.com/news/2025/biontech-bntx-phase-3-data-cero-therapetics-cero-nasdaq-delisting-notice https://www.biopharmcatalyst.com/news/2025/biontech-bntx-phase-3-data-cero-therapetics-cero-nasdaq-delisting-notice"
X Link 2025-09-05T12:40Z 30.2K followers, [----] engagements
"$TRML will be acquired by $NVS for $48/share in cash valuing the deal at $1.4B and representing a 59% premium to the last close and 127% over the 60-day VWAP; the acquisition centers on Tourmalines lead asset pacibekatug targeting inflammation-driven cardiovascular disease and has been unanimously approved by both boards. $REVB $TELO $XLO $SLRX $ONCY $IONS See More Pre-market Movers https://www.biopharmcatalyst.com/news/2025/tourmaline-trml-acquired-by-nvs-revelation-biosciences-revb-phase-1b-data"
X Link 2025-09-09T12:40Z 30.4K followers, [----] engagements
"$ANEB updated its going-private process noting that it has received interest from potential partners and will review all strategic alternatives including a reverse stock split asset sale or merger. $HCWB $IFRX $GRI $COCP $MIRA $SMMT $ANEB $ADXN $TRVI $PROK See More Biotech Updates👇 https://www.biopharmcatalyst.com/news/2025/hcw-biologics-hcwb-68-data-anebulo-aneb-18-going-private https://www.biopharmcatalyst.com/news/2025/hcw-biologics-hcwb-68-data-anebulo-aneb-18-going-private"
X Link 2025-09-12T20:30Z 30.3K followers, [----] engagements
"$CHEK announced a merger with MBody AI an AI stack company. The combined entity to be renamed MBody AI Ltd. will be 90% owned by MBody AI and 10% by Check-Cap. The merger is also expected to synergize with Check-Caps Ghost Kitchen franchise rights in New Jersey. $CHEK $ATYR $GLUE $MESO $RCEL $COCP $SLRX $BIAF $ENTO $INDP $COCP See More Pre-market Movers https://www.biopharmcatalyst.com/news/2025/check-cap-chek-merger-with-mbody-ai-atyr-pharma-atyr-phase-3-fail https://www.biopharmcatalyst.com/news/2025/check-cap-chek-merger-with-mbody-ai-atyr-pharma-atyr-phase-3-fail"
X Link 2025-09-15T12:40Z 30.2K followers, [----] engagements
"$SILO has made initial purchases of Ethereum and Solana as part of its new cryptocurrency treasury strategy signaling a shift toward blockchain integration and real-world asset tokenization alongside its biopharma operations. $NAOV $SILO $DCTH $BIAF $CHEK $ATYR $ADAP $BVS $MTVA $TTNP See More Pre-market Movers https://www.biopharmcatalyst.com/news/2025/nanovibronix-naov-subsidiary-granted-patent-silo-pharma-silo-crypto-purchase https://www.biopharmcatalyst.com/news/2025/nanovibronix-naov-subsidiary-granted-patent-silo-pharma-silo-crypto-purchase"
X Link 2025-09-16T12:40Z 30.4K followers, [----] engagements
"$CODX signed an MoU with a Saudi partner to explore a joint venture that would license and commercialize its molecular diagnostics IP including the upcoming Co-Dx PCR point-of-care platform across the Middle East and North Africa expanding its model similar to its CoSara JV in India. $CODX $BNGO $KLRS $ENTO $HSDT $CHEK $WINT $ADAP $BCDA $ZBIO See More Biotech Updates👇 https://www.biopharmcatalyst.com/news/2025/co-diagnostics-codx-saudi-mou-agreement-bionano-genomics-bngo-offering https://www.biopharmcatalyst.com/news/2025/co-diagnostics-codx-saudi-mou-agreement-bionano-genomics-bngo-offering"
X Link 2025-09-16T20:30Z 30.2K followers, [----] engagements
"$SPRC shares traded higher after AutoMax filed a court motion regarding its merger with a judge granting a stay due to deal uncertainties. AutoMax requested the stay because of potential difficulties meeting closing conditions amid recent business developments according to a filing. $SPRC $CDT $CODX $VANI $ENVB $BIAF $SHPH $SABS $CURX $MTVA See More Biotech Updates👇 https://www.biopharmcatalyst.com/news/2025/scisparc-sprc-judge-granted-stay-cdt-equity-cdt-crypto https://www.biopharmcatalyst.com/news/2025/scisparc-sprc-judge-granted-stay-cdt-equity-cdt-crypto"
X Link 2025-09-17T20:30Z 30.2K followers, [----] engagements
"$REPL said it completed a Type A meeting with the FDA regarding the CRL for its BLA of RP1 plus nivolumab in advanced melanoma with no clear accelerated approval path yet established as the company reviews agency feedback and next steps. $ETNB $REPL $JSPR $RVPH $APVO $BCDA $ADAP $PBM $CDT $SLRX See More Biotech Updates👇 https://www.biopharmcatalyst.com/news/2025/roche-rhhby-acquires-89bio-etnb-replimune-repl-type-a-meeting https://www.biopharmcatalyst.com/news/2025/roche-rhhby-acquires-89bio-etnb-replimune-repl-type-a-meeting"
X Link 2025-09-18T20:31Z 30.3K followers, [----] engagements
"$RVPH priced a public offering of 27M shares and accompanying Series E and F warrants at $0.335 per share raising approximately $9M in gross proceeds to support its late-stage CNS inflammatory and cardiometabolic drug pipeline. $RVPH $VRCA $JSPR $BFLY $IMNN $CMND $CLLS $DVAX $ARTL $APVO See More Pre-market Movers https://www.biopharmcatalyst.com/news/2025/reviva-rvph-9m-offering-verrica-pharmaceuticals-vrca-japanese-approval https://www.biopharmcatalyst.com/news/2025/reviva-rvph-9m-offering-verrica-pharmaceuticals-vrca-japanese-approval"
X Link 2025-09-19T12:40Z 30.3K followers, [----] engagements
"$ANAB plans to split into two public entities by 2026: a royalty-focused firm managing high-value assets like GSK's Jemperli royalties and Vanda milestones and a biopharma progressing rosnilimab (RA UC) ANB033 and ANB101 in immunology. The aim is to unlock value align strategies and enable independent growth. SAN The company will also host a virtual event on October [--] about ANB033 its CD122 antagonist. $SPRC $ANAB $SCYX $KALA $APDN $ARTL $ZURA $CASI $GOVX $ENTA See More Biotech Updates👇 https://www.biopharmcatalyst.com/news/2025/scisparc-sprc-35-acquisition-anaptysbio-anab-32-strategic-plan"
X Link 2025-09-30T20:31Z 30.3K followers, [----] engagements
"$GNPX announced preclinical data showing its lead candidate Reqorsa (quaratusugene ozeplasmid) induced apoptosis and demonstrated strong efficacy in ALK-EML4positive non-small cell lung cancer models. The data to be presented at the AACR-NCI-EORTC Molecular Targets Conference support Reqorsas potential as a gene therapy targeting the TUSC2 tumor suppressor pathway and its use in combination with ALK inhibitors. $GNPX $SCYX $KROS $EYPT $SPRC $EVAX $DMAC $IOBT $ELAB $ENTX See More Pre-market Movers"
X Link 2025-10-15T12:40Z 30.4K followers, 12.5K engagements
"$AVII filing out. S/holder vote 7/10 to change company name to Sarepta Therapeutics Inc $SRPT + voting for 1-for-4 to 1-for-6 reverse split"
X Link 2012-06-01T21:39Z 28.9K followers, [--] engagements
"BioPharmCatalyst updates: $VTUS fails Ph3. $MAPP refile NDA 3Q/4Q. $CYTR Ph2b data '13 + $LXRX $CUR $RPTP http://t.co/DZioFGkB http://bit.ly/MRLmnZ http://bit.ly/MRLmnZ"
X Link 2012-06-26T11:05Z 29.9K followers, [--] engagements
"BioPharmCatalyst updates: $NVO terminate $PCRX agreement. $OSUR FDA approval $CHTP additional trial + $MNOV $PTN $SPPI http://t.co/AApsGeqO http://bit.ly/KROvAx http://bit.ly/KROvAx"
X Link 2012-07-03T20:36Z 28.9K followers, [--] engagements
"BioPharmCatalyst updates: $CRTX Adcom set. $MAPP NDA update + updates for $ZGNX $ITMN $MDVN $AEZS $DVAX $NKTR $CADX http://t.co/HAA4wZzu http://bit.ly/O7WqQi http://bit.ly/O7WqQi"
X Link 2012-07-25T11:14Z 29.8K followers, [--] engagements
"BioPharmCatalyst updates $MAPP PDUFA set. $SPPI files shelf http://t.co/ZsJ9zx6O Other catalysts check the FDA Calendar http://t.co/r4AynIX6 http://bit.ly/w1b1aF http://bit.ly/QbENjL http://bit.ly/w1b1aF http://bit.ly/QbENjL"
X Link 2012-11-22T02:49Z 29.8K followers, [--] engagements
"BioPharmCatalyst updates: http://t.co/n0yCGNcm $DCTH on track for May Adcom. $BLRX data Mar+ $ALNY $CLVS$ INFI $OREX $FOLD $ICPT http://bit.ly/WGpg9D http://bit.ly/WGpg9D"
X Link 2013-01-08T04:10Z 28.9K followers, [--] engagements
"BPC Updates http://t.co/gUIXB31lSq $AFFY $QLTI $RPRX $CRIS $CHTP $CELG $AEZS $ONCY $ACHN $GTXI $CLSN $SYN $IMMU $VVUS $GENT $ITMN $NPSP IMGN http://bit.ly/X567RM http://bit.ly/X567RM"
X Link 2013-02-24T17:44Z 28.9K followers, [--] engagements
"BioPharmCatalyst updates: $ARRY $ALNY $CELG $ISIS $ENTA $CYTR http://t.co/0xGaQ61H0T http://bit.ly/YCeWXn http://bit.ly/YCeWXn"
X Link 2013-05-07T11:04Z 28.9K followers, [--] engagements
"BioPharmCatalyst updates: $CELG $BMRN $RCPT $OPK $BMRN $IDRA $ZGNX $MELA http://t.co/pLWR5dO8QR http://www.biopharmcatalyst.com/June5update http://www.biopharmcatalyst.com/June5update"
X Link 2013-06-06T11:22Z 28.9K followers, [--] engagements
"BioPharmCatalyst updates: $MNKD Adcom set. $BDSI Ph3 data due Jan/Feb + $ATHX $BOTA $ALNY $RIGL $STEM http://t.co/MLCMnHKNqc http://www.biopharmcatalyst.com/jan10updates http://www.biopharmcatalyst.com/jan10updates"
X Link 2014-01-12T00:19Z 28.9K followers, [--] engagements
"RT @chasingthealpha: just donated $10 to www.biopharmcatalyst.com/ great site great catalyst tracker/calendar thats FREE Thanks as always"
X Link 2011-03-03T18:14Z 28.9K followers, [--] engagements
"BioPharmCatalyst updates: $NBIX Ph3 data due Jan + other catalyst dates for $ALDR $MCUR $THLD http://t.co/khFlkG7lDl http://www.biopharmcatalyst.com/Nov3BiotechNews http://www.biopharmcatalyst.com/Nov3BiotechNews"
X Link 2014-11-04T12:45Z 28.9K followers, [--] engagements
"BioPharmCatalyst updates: Updates for $BDSI $BLUE $DVAX $INCY $MEIP $TGTX $IRWD http://t.co/IGiSBYMXNU http://www.biopharmcatalyst.com/LatestPipelineUpdates http://www.biopharmcatalyst.com/LatestPipelineUpdates"
X Link 2014-12-10T12:45Z 28.9K followers, [--] engagements
"BioPharmCatalyst Pipeline updates for $ALKS $ARDX $BMRN $CEMP $EXEL $FLXN $INFI $NKTR $XOMA + more http://t.co/kEbfG0TnMl http://www.biopharmcatalyst.com/Feb24-25BiotechUpdates http://www.biopharmcatalyst.com/Feb24-25BiotechUpdates"
X Link 2015-02-26T12:45Z 28.9K followers, [--] engagements
"BioPharmCatalyst updates: $INCY $SGEN $BMRN $CEMP $CYTK CYTR $EBIO $EXEL $LXRX $MDCO $NBIX THLD THRX TSRO + more http://t.co/ZzM188O5e5 http://www.biopharmcatalyst.com/May1EndofWeekUpdates http://www.biopharmcatalyst.com/May1EndofWeekUpdates"
X Link 2015-05-02T22:12Z 28.9K followers, [--] engagements
"Vry late+doubt anyone up but latest updates $EPCT $VVUS $NBIX $EXEL $MAPP $ALXA $NEOP $LXRX $NPSP $INCY http://bit.ly/m5Nkxu"
X Link 2011-05-04T08:18Z 28.9K followers, [--] engagements
"BioPharmCatalyst updates: $EXEL #PDUFA set for June [--]. $RIGL Ph3 data due mid year + $CORT $NBIX http://www.biopharmcatalyst.com/Jan28UpdatesBPC http://www.biopharmcatalyst.com/Jan28UpdatesBPC"
X Link 2016-01-29T11:59Z 28.9K followers, [--] engagements
"BioPharmCatalyst updates: $ALNY completes Ph3 APOLLO enrollment+ $ARIA $CBYL $DSCO $REPH $TENX $TTHI http://www.biopharmcatalyst.com/Feb1UpdatesBPC http://www.biopharmcatalyst.com/Feb1UpdatesBPC"
X Link 2016-02-02T11:59Z 28.9K followers, [--] engagements
"BioPharmCatalyst updates: $BNHLF expected CRL. $SYN Ph2 trial fail. $ARRY Phase [--] data due [----] + $MDWD $NBIX $HSGX http://www.biopharmcatalyst.com/2016/02/bnhlf-receives-expected-crl-syn-phase-2-trial-fail-arry-phase-3-data-due-2016-mdwd-nbix-hsgx-updates/ http://www.biopharmcatalyst.com/2016/02/bnhlf-receives-expected-crl-syn-phase-2-trial-fail-arry-phase-3-data-due-2016-mdwd-nbix-hsgx-updates/"
X Link 2016-02-03T11:59Z 28.9K followers, [--] engagements
"BioPharmCatalyst updates: $FLML FDA Approval + $ADRO $ALNY $ARGS $CEMP $CERU $GNVC $MACK $MCRB $NWBO $MCRB + more http://www.biopharmcatalyst.com/2016/05/flml-fda-approval-updates-for-adro-alny-args-cemp-ceru-flml-gnvc-mack-mcrb-mrns-nwbo-prtk-rgls-tbra-tnxp-trvn-xncr/ http://www.biopharmcatalyst.com/2016/05/flml-fda-approval-updates-for-adro-alny-args-cemp-ceru-flml-gnvc-mack-mcrb-mrns-nwbo-prtk-rgls-tbra-tnxp-trvn-xncr/"
X Link 2016-05-03T10:59Z 28.9K followers, [--] engagements
"ICYMI: [--] Biotech Stocks to put on your Watchlist: $DPRX $DRRX $GNCA $KITE $MSTX $OPHT $OPXA $PTIE $PTN $VRTX http://biopharmcatalyst.com/news/2016/biotech-stock-watchlist-for-week-commencing-september-19 http://biopharmcatalyst.com/news/2016/biotech-stock-watchlist-for-week-commencing-september-19"
X Link 2016-09-18T20:00Z 28.9K followers, [--] engagements
"Biotech Watchlist 9/26 $ANTH $DPRX $DRRX $GNCA $KITE $MRNS $OPHT $PTN $VRTX +NASH runners $BLRX $GALT $CNAT $GLMD http://biopharmcatalyst.com/news/2016/biotech-stock-watchlist-for-week-of-september-26-2016 http://biopharmcatalyst.com/news/2016/biotech-stock-watchlist-for-week-of-september-26-2016"
X Link 2016-09-24T13:00Z 28.9K followers, [--] engagements
"BPC Week in Review + Jan Event Watch List $DMTX HemB $FGEN Panc+Ph3 China Jan/Feb $NBIX Ph2 $SGYP PDUFA $TENX Ph3 http://biopharmcatalyst.com/news/2017/biopharmcatalyst-expands-coverage-biotech-week-in-review-six-upcoming-january-catalysts http://biopharmcatalyst.com/news/2017/biopharmcatalyst-expands-coverage-biotech-week-in-review-six-upcoming-january-catalysts"
X Link 2017-01-14T14:30Z 28.9K followers, [--] engagements
"Biotech Movers 04/26 $AKBA $FLKS $BPMX $FLXN offerings Pipeline updates $ABIO $AZN ARTIC delay $JAZZ $ALNY $RARX https://biopharmcatalyst.com/news/2017/flexion-flxn-slumps-on-notes-offering-akebia-akba-maintains-upward-momentum https://biopharmcatalyst.com/news/2017/flexion-flxn-slumps-on-notes-offering-akebia-akba-maintains-upward-momentum"
X Link 2017-04-27T00:01Z 28.9K followers, [--] engagements
"Biotech Wk in Review 5/19+ Upcoming non-ASCO catalysts for: $AZN $ALDR $ALNY $BLUE $CARA $MTNB $NVS $PBYI $PTLA https://www.biopharmcatalyst.com/news/2017/upcoming-non-asco-biotech-stock-catalysts-biotech-week-in-review-may-19-2017 https://www.biopharmcatalyst.com/news/2017/upcoming-non-asco-biotech-stock-catalysts-biotech-week-in-review-may-19-2017"
X Link 2017-05-20T23:56Z 28.9K followers, [--] engagements
"Biotech Review+ [--] catalysts left for Sept $ABUS/ $ALNY $AXON $BCRX $FCSC $FOLD $NBRV $PRQR $PTCT $RDHL $VSAR $ZGNX https://www.biopharmcatalyst.com/news/2017/12-biotech-catalysts-to-round-out-september-biotech-week-in-review-september-15-2017 https://www.biopharmcatalyst.com/news/2017/12-biotech-catalysts-to-round-out-september-biotech-week-in-review-september-15-2017"
X Link 2017-09-15T20:24Z 28.9K followers, [--] engagements
"Biotech Wk in Review 9/29+ upcoming biotech events- early Oct: $ACRX $AERI $CAPR $FENC $FOLD $FLXN $ONCE $RDHL $SRPT https://www.biopharmcatalyst.com/news/2017/10-biotech-events-for-the-first-two-weeks-of-october-2017-week-in-review-09-29-2017 https://www.biopharmcatalyst.com/news/2017/10-biotech-events-for-the-first-two-weeks-of-october-2017-week-in-review-09-29-2017"
X Link 2017-09-30T23:36Z 28.9K followers, [--] engagements
"@libraryinvestor Potentially something to add for BPC looking 6-12 months ahead.can imagine that it would be $pricey to set up though"
X Link 2017-10-03T23:46Z 29.9K followers, [--] engagements
"11/2 AH Pipeline Updates added: $ABUS $APRI $AXON $CALA $CARA $CRVS $MYOK $RARE $RDUS $RVNC $SPPI $VRX $VYGR https://x.com/crusadernz/status/926239060187738112 https://www.biopharmcatalyst.com/news/2017/ocera-ocrx-72-on-acquisition-alnylam-alny-10-on-positive-attr-data Biotech updates 11/2 $OCRX buyout +72% $ALNY +ve ATTR data $IONS + $KPTI $PGNX $SAGE $SGEN $SNSS $TRVN $VRX + more https://t.co/L1TVHzfY8J https://x.com/crusadernz/status/926239060187738112 https://www.biopharmcatalyst.com/news/2017/ocera-ocrx-72-on-acquisition-alnylam-alny-10-on-positive-attr-data Biotech updates 11/2 $OCRX"
X Link 2017-11-03T09:55Z 28.9K followers, [--] engagements
"$ALNY files mixed shelf $150m. Filing - http://bit.ly/rovbOZ"
X Link 2011-07-21T20:46Z 28.9K followers, [--] engagements
"Upcoming 1Q [----] PDUFA and Advisory Committee dates; Biotech Wk in Review 12/22: $ARDM $APRI $GILD $LLY $LPCN $KMPH $OTIC $PCRX $SGYP $VRTX https://www.biopharmcatalyst.com/news/2017/pdufa-and-advisory-committee-meeting-dates-for-1q-2018-biotech-stock-week-in-review https://www.biopharmcatalyst.com/news/2017/pdufa-and-advisory-committee-meeting-dates-for-1q-2018-biotech-stock-week-in-review"
X Link 2017-12-24T20:11Z 28.9K followers, [--] engagements
"Biotech Updates 1/31: $CASC acquired by $SGEN $VRTX to proceed Ph3 CF triple $ALKS files depression NDA $SAGE promising insomnia data $ONCS offering + $BGNE $CARA $CBIO $DERM $GEMP $JNP $LLY $MNOV $ZGNX https://www.biopharmcatalyst.com/news/2018/cascadian-casc-soar-71-on-acquisition-by-seattle-genetics-sgen-vertex-vrtx-to-proceed-with-phase-3-cf-triple-regimen https://www.biopharmcatalyst.com/news/2018/cascadian-casc-soar-71-on-acquisition-by-seattle-genetics-sgen-vertex-vrtx-to-proceed-with-phase-3-cf-triple-regimen"
X Link 2018-02-01T01:02Z 28.9K followers, [--] engagements
"Biotech Updates 02/01: $ALNY patisiran PDUFA 8/11 $SLGO IPO pipeline added $ICPT Ocaliva label update $AGN AVYCAZ sNDA approval $AFMD +40% lymphoma data + $AMGN $CYAD $IMRN updates. https://www.biopharmcatalyst.com/news/2018/intercept-icpt-announces-ocaliva-label-update-affimed-afmd-shares-up-on-updated-lymphoma-data https://www.biopharmcatalyst.com/news/2018/intercept-icpt-announces-ocaliva-label-update-affimed-afmd-shares-up-on-updated-lymphoma-data"
X Link 2018-02-01T23:46Z 28.9K followers, [--] engagements
"Biotech Updates 2/8: $TEVA -11% on warning letter $GEMP -28% on offering $JNJ ZYTIGA prostate approval $RNN discontinues RCC $MDGL meets endpoint but -10% + $ABEO $ALNY $ALXN $MEIP pipeline updates https://www.biopharmcatalyst.com/news/2018/teva-shares-slip-on-likely-regulatory-delay https://www.biopharmcatalyst.com/news/2018/teva-shares-slip-on-likely-regulatory-delay"
X Link 2018-02-09T02:11Z 28.9K followers, [--] engagements
"Biotech Events left slated for Feb + Week in Review: $AMAG / $ATRS $AIMT $APRI $KDMN $KMPH $KURA $MRNS $NVAX $PCRX $SRNE $VRTX https://www.biopharmcatalyst.com/news/2018/11-upcoming-biotech-stock-events-slated-for-february-biotech-week-in-review https://www.biopharmcatalyst.com/news/2018/11-upcoming-biotech-stock-events-slated-for-february-biotech-week-in-review"
X Link 2018-02-10T22:40Z 28.9K followers, [--] engagements
"Biotech updates 02/12/2018: $AXON CEO resigns -20% $VRTX CF approval $DARE +50% license deal $FOLD PDUFA Aug [--] $KDMN +21% $CBIO $AFMD offerings https://www.biopharmcatalyst.com/news/2018/axovant-axon-ceo-resigns-shares-20-vertex-vtrx-cf-approval-dare-50-on-license-agreement https://www.biopharmcatalyst.com/news/2018/axovant-axon-ceo-resigns-shares-20-vertex-vtrx-cf-approval-dare-50-on-license-agreement"
X Link 2018-02-13T01:32Z 28.9K followers, [--] engagements
"Biotech updates 2/14: $BIIB -7% Alzheimer's update $NKTR p/ship $BMY $AMAG $ATRS approval $AMGN BLINCYTO Adcom 3/7; $GLMD fail -42% $CDMO $FOLD offerings $VRX PDUFA 10/5 + $ATNX $AGIO $ALKS $ICPT $MYOK $NBIX $PRTA $SNNA $VNDA $VRTX https://www.biopharmcatalyst.com/news/2018/nektar-nktr-seals-partnership-with-bristol-myers-bmy-galmed-glmd-shares-slide-on-mid-stage-trial-fail https://www.biopharmcatalyst.com/news/2018/nektar-nktr-seals-partnership-with-bristol-myers-bmy-galmed-glmd-shares-slide-on-mid-stage-trial-fail"
X Link 2018-02-15T01:27Z 28.9K followers, [--] engagements
"Upcoming key Phase [--] Biotech Catalysts left for 1Q + wk in Review: $AIMT $ANTH $BHVN $CLSD $DERM $ESPR $GWPH $IMGN $NBIX $NRBV (spring) $REGN $VBLT $VTVT https://www.biopharmcatalyst.com/news/2018/phase-3-biotech-catalysts-to-watch-1q-2018-biotech-week-in-review https://www.biopharmcatalyst.com/news/2018/phase-3-biotech-catalysts-to-watch-1q-2018-biotech-week-in-review"
X Link 2018-02-17T12:12Z 28.9K followers, [--] engagements
"Biotech Updates 2/21: $ABBV $NBIX +ve data $ANTH +44% on Roth PT $10 $GWPH Ph2 fail + Adcom 4/19 $DVAX ACIP approval + $ATOS $NERV $BLUE $GWPH pipeline updates https://www.biopharmcatalyst.com/news/2018/abbvie-abbv-neurocrine-nbix-late-stage-positive-data https://www.biopharmcatalyst.com/news/2018/abbvie-abbv-neurocrine-nbix-late-stage-positive-data"
X Link 2018-02-22T01:06Z 28.9K followers, [--] engagements
"Dec catalysts Pt2: Ph3 data $VVUS $CORT $INCY Ph2 data $CAPS $CYCC $IMMU $CYTK $INHX $VPHM. Calendar - http://bit.ly/aiki0d"
X Link 2010-11-30T18:17Z 28.9K followers, [--] engagements
"11 PDUFA and Advisory Committee Meeting dates for March and April (small/mid-cap) + Biotech Wk in Review $CLVS $GWPH $MNK $NBIX $OTIC $PCRX $PGNX $RARE $RIGL $SRNE (2/28) $THERF https://www.biopharmcatalyst.com/news/2018/11-pdufa-and-advisory-committee-meeting-dates-for-march-and-april-small-and-mid-cap https://www.biopharmcatalyst.com/news/2018/11-pdufa-and-advisory-committee-meeting-dates-for-march-and-april-small-and-mid-cap"
X Link 2018-02-24T21:42Z 29.8K followers, [--] engagements
"Biotech Updates 02/28: $SRNE FDA Approval $ECYT +41% $AGN PDUFA delayed till August $ACAD $TSRO $VRX slide on earnings $CORI offering + updates for $BCRX $CANF $CMTA $MBVX $TCON $HTBX $NVAX https://www.biopharmcatalyst.com/news/2018/sorrento-srne-18-on-fda-approval-endocyte-ecyt-41-on-positive-offering https://www.biopharmcatalyst.com/news/2018/sorrento-srne-18-on-fda-approval-endocyte-ecyt-41-on-positive-offering"
X Link 2018-02-28T23:04Z 29.8K followers, [--] engagements
"Biotech Stock Updates 3/6: $THERF FDA Approval +30% $BMY Approval $CLSD offering $PLX data March $RIGL data+PDUFA April $GLYC -18% + $AGLE $ALNA $BHVN $BIVV $BLRX $CTXR $RGNX $ZFGN $ZGNX updates https://www.biopharmcatalyst.com/news/2018/theratechnologies-therf-fda-approval-marinus-mrns-14-on-data-delay https://www.biopharmcatalyst.com/news/2018/theratechnologies-therf-fda-approval-marinus-mrns-14-on-data-delay"
X Link 2018-03-07T01:07Z 29.8K followers, [--] engagements
"10 Biotech Stock Events to round out 1Q 2018; Biotech Stock Week in Review $ALT $ANAB $ARMO $BHVN $CDTX $CLLS $FLKS $IMGN $PTGX $TSRO https://www.biopharmcatalyst.com/news/2018/biotech-stock-events-to-round-out-1q-2018-biotech-stock-week-in-review https://www.biopharmcatalyst.com/news/2018/biotech-stock-events-to-round-out-1q-2018-biotech-stock-week-in-review"
X Link 2018-03-17T12:13Z 29.9K followers, [--] engagements
"Biotech updates 03/19: Data out for $HRTX +27% $ARNA +25% $CDTX -24% $PSDV PDUFA 11/5 $PTIE Adcom 6/26 Offerings $PTI $GLYC $XNCR Pipeline updates for $LIFE $AGIO $BYSI $DNLI $FCSC $MDWD https://www.biopharmcatalyst.com/news/2018/heron-hrtx-27-and-arena-arna-23-surge-on-data https://www.biopharmcatalyst.com/news/2018/heron-hrtx-27-and-arena-arna-23-surge-on-data"
X Link 2018-03-19T23:06Z 29.8K followers, [--] engagements
"Upcoming Biotech Catalysts for April + Wk in Review: $GWPH $IMGN $INCY $KPTI $NBRV $PCRX $PFSCF $RARE $RIGL $SELB $VTVT (+ March $ANAB $BHVN ) https://www.biopharmcatalyst.com/news/2018/upcoming-biotech-stock-catalysts-for-april-biotech-week-in-review https://www.biopharmcatalyst.com/news/2018/upcoming-biotech-stock-catalysts-for-april-biotech-week-in-review"
X Link 2018-03-24T14:21Z 29.8K followers, [--] engagements
"Biotech Stock Updates 3/29: Offerings $ZSAN -45% $PULM -31% $INSM $CPRX NDA filings $MNOV fail -15% $PFE data $ALNY -9% $AKCA -13% + $AKTX $ARMO $GALT pipeline updates. https://www.biopharmcatalyst.com/news/2018/zosano-zsan-slides-on-offering-45-medicinova-mnov-fails-mid-stage-trial-15 https://www.biopharmcatalyst.com/news/2018/zosano-zsan-slides-on-offering-45-medicinova-mnov-fails-mid-stage-trial-15"
X Link 2018-03-29T23:22Z 29.9K followers, [--] engagements
"Upcoming Regulatory Dates in April/May: PDUFA dates: $DOVA $KTOV $LPCN $RARE $REPH $RIGL $TXMD $VRX; Advisory Committee: $AKCA $AKAO $GWPH $INCY $INSY $SIGA https://www.biopharmcatalyst.com/news/2018/upcoming-pdufa-dates-and-advisory-committee-meetings-for-april-may https://www.biopharmcatalyst.com/news/2018/upcoming-pdufa-dates-and-advisory-committee-meetings-for-april-may"
X Link 2018-04-14T12:55Z 28.9K followers, [--] engagements
"Biotech Stock Updates 04/17: $RIGL $RARE FDA Approval $GWPH +ve Adcom notes +11% $NVCR +8% $APLS -17% offering + Pipeline updates for $RCUS $PTI $VBIV https://www.biopharmcatalyst.com/news/2018/fda-awards-approval-to-both-rigel-rigl-and-ultragenyx-rare-gwph-receives-boost-heading-into-advisory-committee-meeting https://www.biopharmcatalyst.com/news/2018/fda-awards-approval-to-both-rigel-rigl-and-ultragenyx-rare-gwph-receives-boost-heading-into-advisory-committee-meeting"
X Link 2018-04-18T00:01Z 28.9K followers, [--] engagements
"Biotech Updates 04/25: $ACAD -22% CNN report $DARE +57% $ABBV files Psoriasis BLA $SNY flu PDUFA 1/28 ASCO abstract titles out - Pipeline updates $ARMO $AVXS $BMRN $CALA $CANF $CNCE $DCPH https://www.biopharmcatalyst.com/news/2018/acadia-acad-shares-22-on-cnn-report-asco-2018-abstract-titles-out https://iplanner.asco.org/am2018/ https://www.biopharmcatalyst.com/news/2018/acadia-acad-shares-22-on-cnn-report-asco-2018-abstract-titles-out https://iplanner.asco.org/am2018/"
X Link 2018-04-26T00:05Z 29.9K followers, [--] engagements
"Biotech stock updates 04/30: $KPTI +25% on STORM data $STDY acquired +77% $AZRX offering $NVS Tafinlar approval $REGN $SNY cemiplimab PDUFA 10/28 $MRK KEYNOTE-189 PDUFA 9/23 + Pipeline updates for $AGN $BOLD $CNAT $GNCA $NBIX $NKTR $QURE $RCKT $VYGR $ABLX"
X Link 2018-04-30T22:53Z 29.9K followers, [--] engagements
"Biotech Stock Events on watch for May; Biotech Week in Review Data: $BOLD $EBIO $JNJ $BMRN $URGN $NBRV $RCKT $MDGL PDUFA/Adcom; $AKCA $INSY $DOVA $REPH $KTOV $TXMD $LPCN https://www.biopharmcatalyst.com/news/2018/biotech-stock-catalysts-on-watch-for-may-biotech-week-in-review https://www.biopharmcatalyst.com/news/2018/biotech-stock-catalysts-on-watch-for-may-biotech-week-in-review"
X Link 2018-05-05T13:44Z 28.9K followers, [--] engagements
"Biotech Updates 05/10: $ARMO +67% $LLY buyout $AKCA $IONS +ve Adcom vote $RHHBY $EXEL IMblaze fail + wrap of 1Q earnings pipeline updates https://www.biopharmcatalyst.com/news/2018/armo-shares-67-on-acquisition-akcea-akca-and-ionis-ions-score-positive-vote-by-fda-panel-exelixis-exel-14-on-late-stage-fail https://www.biopharmcatalyst.com/news/2018/armo-shares-67-on-acquisition-akcea-akca-and-ionis-ions-score-positive-vote-by-fda-panel-exelixis-exel-14-on-late-stage-fail"
X Link 2018-05-11T02:43Z 29.9K followers, [--] engagements
"15 PDUFA/Advisory Committee dates slated for May/June: $AKAO $AMGN $ARRY $BMRN $DERM $DOVA $DRRX $GWPH $INCY $INSY $KTOV $LLY $PTIE $REPH $SCPH $TXMD $VRX https://www.biopharmcatalyst.com/news/2018/15-advisory-committee-and-pdufa-dates-slated-for-may-and-june-biotech-week-in-review https://www.biopharmcatalyst.com/news/2018/15-advisory-committee-and-pdufa-dates-slated-for-may-and-june-biotech-week-in-review"
X Link 2018-05-13T13:30Z 28.9K followers, [--] engagements
Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing